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Membrane proteins are omnipresent in biological systems, being estimated to make up 
20-30 % of genome encoded proteins.[1] Functions of those immensely important macromol-
ecules range from ion transport over signal transduction to catalysis and many more.[2,3] One 
particularly relevant species of those structures are transmembrane proteins, spanning 
through lipid bilayers and thus anchoring the proteins in the membrane environment. Re-
search in this interesting field of protein chemistry has especially generated great relevance 
since the current pandemic with the SARS-CoV-2 genome also encoding transmembrane 
proteins which are linked to the process of infection.[4] Another prominent example in the 
field of transmembrane proteins is bacteriorhodopsin, which consists of seven α-helical 
transmembrane units, being able to transport protons across lipid membranes.[5] In general, 
analysis of such proteins proved to be challenging since their acquisition can be limited by 
low expression rates or complex, multi-step synthetic routes.[6] Therefore, the need for sim-
plified model systems arises in order to gain more accessible insights in those biological 
processes.  
A great and commonly used class of peptidomimetics are β-peptides, consisting of β-amino 
acids. Due to their additional methylene unit in the amino acid backbone, β-peptide helices 
are much more versatile compared to their α-analogues while still forming similar helices 
like the 12- or the 14-helix.[7] Furthermore, the peptides are immune to natural proteolysis 
and form substantially more stable helices. Generating well-known and characterized helices 
with a minimal amount of six amino acids in aqueous media, β-peptides are perfectly suitable 
for the use as model systems to mimic natural α-peptides.[8]  
In the DIEDERICHSEN group, preliminary studies dealt with secondary structure regulation of 
transmembrane β-peptides by substitution of single amino acids with cyclic amino acids.[9] 
In addition, transmembrane 14-helices were characterized in lipid bilayers and aggregation 
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studies were performed with incorporated glutamine moieties.[10,11] Thereby, a transmem-
brane model system was established which is suitable for further aggregation studies in lipid 
membranes.[12]  
Other studies on deca-β3-peptides with incorporated cyanuric acid (CA) and melamine (M) 
building blocks lead to the self-assembly of helix bundles in the aqueous phase, consisting 
of six peptides according to the CA∙M lattice.[13] Well-studied CA∙M interactions were uti-
lized to create supramolecular rosette structures, bearing a cavity of 4 Å in the middle of this 
hexagon. Multiple layers of pure CA∙M aggregates were also shown to create channels by 
self-assembly.[14]  
In the first part of this work, CA∙M building blocks were synthesized and incorporated into 
an elongated transmembrane model system. The peptides were designed in a way that the 
aggregation takes place in the outer-membrane environment, similar to previous studies on 
molecular recognition by nucleobase pairing.[15] Potential aggregation and channel for-
mation by these peptides and the transmembrane model system itself were examined with 
various assays. FÖRSTER resonance energy transfer (FRET) efficiency measurements of the 
pure transmembrane domain, similar to STOLLBERG (née ROST), were performed by the in-
troduction of two fluorophores. Proton transport assays to determine the channel function of 
peptides were performed by D. RUPPELT from the STEINEM group. Furthermore, membrane 
conductivity measurements with incorporated peptides were executed in collaboration with 
A. MAZNICHENKO from the POHL group. 
The second part of this thesis deals with the development of a novel transmembrane β-pep-
tide molecular ruler. In general, molecular rulers reveal inter- and intramolecular distances 
on the nanometer or even ångström scale. For example, this can be determined by X-ray 
studies, spectroscopical methods like nuclear magnetic resonance (NMR) and electron par-
amagnetic resonance (EPR) or by fluorescence techniques.[16–19]  
Especially, the near-membrane environment is an important location to study since present 
ion concentrations are linked to vital processes like membrane fusion.[20] β-Peptidic trans-
membrane 14-helices promote themselves for the application as molecular rulers due to their 
intrinsic stability and rigidity. Literature-known and well-characterized dimensions of these 
helices lead to the possibility of defined spatial positioning of probes at the peptide side 
chain in different distances in regard to the membrane.   
Here, two transmembrane β-peptides were synthesized as a proof of concept for the use as 
molecular rulers. Differing in length, both peptides were N-terminally labeled with Atto643 
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and incorporated into lipid bilayers. Graphene-based metal-induced energy transfer (gra-
pheneMIET) measurements were performed by A. SHARMA from the ENDERLEIN group, cal-
culating the axial heights of the fluorophores with respect to the substrate surface. This tech-
nique enables determination of ångström distances, utilizing the energy transfer from the 
Atto643 dye to a single sheet of graphene. The use of these transmembrane peptides enables 
a novel approach to molecular rulers, being synthetically available with medium effort and 
being easily modifiable with probes like proton, calcium or other ion sensors. With this, ion 





























2 Fundamentals of β-Amino Acids and 
β-Peptides 
 
Since both topics of this work are dealing with the synthesis and application of β3-peptides, 
the following chapter will give a general overview of the concept of β3-D-amino acids and 
especially their properties when it comes to the formation of peptides. In addition, prelimi-
nary work on the aggregation and orientation of those peptides is presented in the context of 
incorporation into lipid membranes as well as temperature dependent aggregation studies. 
 
2.1 β-Amino Acids 
 
The interest in understanding biological processes into detail has substantially risen over the 
last century, peaking even more since the current pandemic crisis.[21,22] In order to obtain full 
insight into specific functions of proteins or biological systems in general, large protein com-
plexes, inter- and intramolecular interactions, differing membrane compositions, surround-
ings and a lot more variables have to be considered and evaluated. The problem that one is 
facing while dealing with these systems is that they are too complex to be understood in 
detail without breaking down the system in much simpler parts.[23] In addition, when work-
ing with proteins or peptides, the expression of those is often not easy and synthetic ap-
proaches are limited to the number of amino acids in the sequence.[24] Therefore, artificial 
model systems come in handy, which are simplifying biological processes and making them 
more accessible to be understood step by step.[25]  
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One of the more prominent as well as already widely examined model systems are β-pep-
tides, consisting of β-amino acids and similarly to α-peptides, they are capable of forming a 
variety of helices and other secondary structures.[26–31] Promising properties are being less 
prone to proteolysis and forming stable secondary structures with only six amino acids with 
modulatable helices depending on the sequence.[9,32–34]  
β-Amino acids differ from their α-analogues in an additional methylene unit in the backbone 
which is located between the carboxylic and the amino function of the respective amino acid 
(Figure 1).[35] Depending on the location of the residue, different isomers are possible, rang-




Figure 1: General structure of β-amino acids compared to an α-analogue. Starting to count at the carboxylic 
carbon atom, β2-amino acids are substituted at position C-2, whereas β3-amino acids are substituted at position 
C-3. Disubstitution of amino acids leads for example to β2,3-amino acids. 
 
β-Amino acids are rarely found in nature. However, they were extracted from several pro-
karyotic and eukaryotic species. For example, β3-lysine can only be found in some bacteria, 
whereas β3-phenylalanine is present in bacteria as well as in certain plants and fungi.[36] On 
the other hand, derivatives of β-alanine can be found in pantothenic acid (vitamin B5).
[37] 
Synthetically, β3-amino acids, which are used in this work, are accessible via the ARNDT-
EISTERT-homologation (Scheme 1).[38,39]  
 
 
Scheme 1: Schematic synthesis of a β3-amino acid with the ARNDT-EISTERT-homologation. The N-protected 
(PG) α-analogue is converted into a diazo ketone with the use of diazomethane, followed by a silver(I) cata-
lyzed WOLFF-rearrangement. 
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Thereby, the respective N-protected α-analogue is treated with diazomethane in order to con-
vert it into a diazo ketone. In a WOLFF-rearrangement, the diazo ketone is then further mod-
ified, resulting in the final β3-amino acid.[40]  Following this general procedure, β3-amino 
acids can be synthesized based on their commercially available α-analogues with relatively 
low effort and sufficient yields. However, it has to be mentioned that there is also a variety 
of other synthetic procedures to obtain these kind of amino acids.[37,41–43] In contrast, β2-
amino acids are significantly more challenging to obtain due to the new stereogenic center, 
which has to be generated. Former strategies focused on auxiliary-based syntheses, followed 
by just recent developments in the synthesis of polar side chain containing β2-amino acids 
via a collective synthesis.[44,45]  
 
2.2 β-Peptides  
 
Due to the backbone elongation in β-amino acids and thus the additional C-C bond, new 
rotation possibilities arise. Thereby, torsional angles ω, φ, θ and ψ (Figure 2) can be defined 
according to BALARAM and used to predict and modulate secondary structure formation.[27,46]  
 
 
Figure 2: Notation of the rotational angles according to BALARAM.[27,46] 
 
Counterintuitively, it was shown that the higher amount of freely rotatable bonds in β-amino 
acids leads to more stable and more rigid peptide helices compared to their α-analogues, 
already forming helices with six amino acids instead of 15-20 in the aqueous phase.[30,31,33] 
Regarding the angle θ which describes the rotation between C-2 and C-3, there is evidence 
that a trans conformation favors sheet-like structures (Figure 3).[47,48] Also, CHENG et al. 
stated that a gauche conformation is required to form helical structures.[27] Different substi-
tutions of the β-amino acids lead to different secondary structures which was already well 
examined experimentally as well as theoretically.[49–53] When positions C-2 or C-3 are sub-
stituted with hydrophobic residues, a gauche conformation is favored, even more with both 
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positions being substituted.[54] Furthermore, cyclic amino acids like trans-2-aminocyclo-
hexanecarboxylic acid (ACHC) or trans-2-aminocyclopentanecarboxylic acid (ACPC) 
enforce a gauche conformation due to their geometric constraints.[55–57]  
 
 
Figure 3: The NEWMAN projection of β-alanine shows two possible rotamers for the rotation between C-2 and 
C-3. Gauche conformations support helix formation, whereas trans conformation enforces sheet-like struc-
tures.[27] 
 
One of the most prominent secondary structure elements of the β-peptides is the so-called 
14-helix (Figure 4). In these helices, hydrogen bonds are formed between amide protons at 
position i and carbonyl oxygen atoms at position i+2. Counting all atoms among this intra-
molecular interaction, a 14-membered ring can be described, leading to the notation of a 14-
helix. Across the field of β-peptide literature, nomenclature is not always consistent, there-
fore a variety of notations for the helices can be found. For example, L+2, 2L, 14-helix, 31-
helix and 314-helix all describe the same secondary structure.
[33,58]   
 
 
Figure 4: Selection of β-peptide helices and their nomenclature. The respective number indicates the amount 
of atoms in between hydrogen bonds after helix formation.[27] 
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First analyses of β-peptides were performed via fiber diffraction and infrared (IR) measure-
ments, leading to the discovery of helical structures.[59,60] A deeper insight was gained with 
NMR and X-ray studies while enforcing a 14-helix by the use of ACHC. Thereby, it was 
shown that these helices are formed in organic solvents as well as in solid state.[55,61,62] The 
14-helix is perfectly suitable for the role of a model system for α-helices while being more 
rigid and having three amino acids per turn, resulting in every residue at position i+3 being 
stacked above the residue at position i (Figure 5).[33,63] Utilizing this fact, the 14-helix can 
be described with three flanks and modified in a way that intramolecular interactions (e.g. 
π-stacking or electrostatic interactions) between specific residues can be enforced. 
 
 
Figure 5: Structural differences between α-helices (3.613-helix) and 14-helices (314-helix). Handedness of the 
14-helices can be modulated by the use of D/L β-amino acids.[64] 
 
In addition to the different torsional angles in α- and 14-helices, the helices also differ in 
their dimensional properties. The inner radius of a 14-helix (2.7 Å) is wider compared to the 
α-analogue (2.2 Å). Also, there are more residues per turn in α-helices (3.6 vs. 3.0 in 14-
helices) with the rise per residue being smaller (1.5 Å vs. 1.56 Å in 14-helices).[65,66]  
In order to work with 14-helices, one has to understand how stabilization of the helical struc-
ture can be ensured in the desired medium. In organic solvents, α-helices are formed with 
10-12 amino acids, whereas the 14-helix in general only needs six β-amino acids to establish 
a stable helix.[33,54,63] The GELLMAN group even presented a β-peptide consisting only of four 
ACHC moieties which adapted a 14-helix in solid state.[8] WU et al. proposed that the aston-
ishing ability to form a helix with just as few as four amino acids in organic solvents might 
arise from electrostatic interactions between nitrogen and carbon atoms in the amide 
FUNDAMENTALS OF β-AMINO ACIDS AND β-PEPTIDES                                                                
10 
bond.[51,67,68]  
However, this exceptional property is limited to organic solvents whereas in aqueous media, 
14-helices are significantly less stable.[27,61] It was shown that hexa-β-peptides only form 
helices in water with a sufficient amount of cyclic amino acids like ACHC.[61] Exchanging 
these highly 14-helix promoting amino acids with non-cyclic derivatives showed low ten-
dency towards helix formation. A possible explanation was delivered by taking side chain 
interactions into account. In α-helices, positions i and i+4 have a distance of roughly 6.3 Å 
with an angle of 40° between them. However, in 14-helices positions i and i+3 are closer 
with 5 Å and almost parallel. Therefore, it was proposed that side chain interactions are 
playing an important role in the formation of 14-helices. In aqueous media, these interactions 
are minimized due to the present water which is competing with these electrostatical inter-
actions. Similar behavior is observed for β-sheet structures in α-peptides.[69–71]    
CHENG and DEGRADO as well as ARVIDSSON et al. developed modified 14-helix using β-
peptides which were stabilized by electrostatic interactions in the amino acid side 
chains.[72,73] 14-Helix flanks (positions i and i+3 respectively) were equipped with alternat-
ing β-glutamine and β-lysine or β-ornithine derivatives so that electrostatic interactions 
could occur upon helix formation.  
In contrast to these findings, PAHLKE recently analyzed a sequence of alternating β3-D-valine 
and β3-D-lysine moieties in a nonapeptide.[74] Thereby, 14-helix formation was clearly shown 
via circular dichroism (CD) spectroscopy (Figure 6), indicating that at a certain length, 14-
helices are able to form in aqueous media. Based on these measurements, the 14-helices are 
no longer bound to organic solvents or membrane surroundings but can also be generated in 
water. 























 / nm  
Figure 6: CD spectrum of an alternating sequence of a nonapeptide with β3-D-lysine and β3-D-valine. In 
general, minima around 195 nm and maxima around 215 nm indacte a clear right-handed 14-helix 
formation.[27,74] 
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2.3 Artificial Transmembrane β-Peptides  
 
It is estimated that 30 % of all natural proteins are membrane proteins and therefore interact 
with biological membranes to accomplish various functions like signal transduction, enzyme 
activity, transport of ions and other vital processes.[75–79] Since the demanding environment 
of proteins is crucial for their function, the analysis of those highly complex structures can 
be quite difficult.[75]  
Breaking down these systems to a minimized level of complexity was for example achieved 
by KILLIAN by introducing transmembrane model systems like WALP.[80,81] For this pur-
pose, alternating sequences of leucine and alanine in different lengths were synthesized and 
flanked by two tryptophans respectively.[82] Membrane insertion and especially the influence 
of hydrophobic lengths of the peptides on hydrophobic mismatches of the membrane were 
shown (Figure 7). A hydrophobic peptide core that is longer than the hydrophobic thickness 
of a membrane leads to a positive hydrophobic mismatch and vice versa.[83] The biological 
membrane can adapt to this length differences in different ways. On the one hand, the mem-
brane can stretch, shrink or even form a non-bilayer phase. On the other hand, the peptide or 
protein itself can form aggregates or tilt in order to slightly change its hydrophobic length. 
Another model system, KALP, showed the same results with the difference of having lysine 
residues in the sequence instead of tryptophans.[84–87]  
 
 
Figure 7: Schematic view on a positive mismatch. Since the transmembrane domain length (dTM) is longer 
than the membrane bilayer hydrophobic thickness (dHT), the membrane can adapt by stretching.[88]  
 
Based on this knowledge and the advantages of β-peptides, especially in the shape of 14-
helices, the DIEDERICHSEN group specialized on the synthesis, characterization and organi-
zation of such KALP- and WALP-inspired transmembrane peptides.[12,74,89,90]  
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PAHLKE synthesized a variety of different transmembrane β-peptides with high β3-D-leucine, 
β3-D-isoleucine or β3-D-valine contents to obtain 12- and 14-helices. It was shown that the 
introduction of ACHC, similar to the findings of GELLMAN, DEGRADO and SEEBACH, con-
verts 12-helices to 14-helices, making β-peptides a desirable class of transmembrane model 
systems due to their modulatable structure.[9,74] The integrity of the peptides was proven via 
tryptophan’s intrinsic fluorescence properties. It is known that tryptophan has an absorption 
maximum under 330 nm in hydrophobic environments, whereas the maximum shifts to over 
330 nm in hydrophilic environments due to an electron density shift in the indole moi-
ety.[91-94] Transmembrane β-peptides were equipped with a β3-tryptophan residue either in 
the middle of the sequence or N-terminally. The occurring shifts of the β3-tryptophan ab-
sorption gave evidence about the successful incorporation of the synthesized peptides into 
lipid membranes.[74]  
Furthermore, similar β-peptides were equipped with a novel diiodo-compound to locally in-
crease the electron density in defined positions. X-ray diffraction measurements revealed the 
position of these compounds, being successfully incorporated into the lipid membrane. Since 
the peptide was designed with a longer hydrophobic part compared to the membrane (Figure 
8), a positive mismatch was observed, resulting in tilting of the peptides by 16°.[10,12]  
 
 
Figure 8: Transmembrane model system developed by STOLLBERG with a hydrophobic core of 19 consecutive 
β3-D-valines, flanked by two β3- D-tryptophans and two β3- D-lysines.[12] 
 
Based on this new standard model system, β3-glutamine amino acids were incorporated into 
the sequence in order to analyze the non-covalent aggregation of those peptides in lipid 
membranes. Measuring and evaluating the FRET efficiency, trimeric aggregation states 
could be found when incorporating two or three β3-glutamine moieties at 25 °C.[11] Temper-
ature-dependent fluorescence spectroscopy measurements revealed that the stability of asso-







3 Synthesis of Transmembrane β-Pep-
tides for the Organization in Lipid 
Bilayers 
 
Since protein aggregation is key to many vital processes, scientists have been extensively 
investigating this biochemical phenomenon in the last decades. In this chapter, the aggrega-
tion behavior of artificial transmembrane β-peptide model systems is examined based on 
non-covalent hydrogen bonding induced by cyanuric acid (CA) and melamine (M) recogni-
tion units. Design, synthesis and labeling strategies are presented as well as the surprising 
comparison to the pure transmembrane domain. Further analyses included fluorescence-
based proton transport assays in collaboration with D. RUPPELT, membrane conductivity 
measurements in cooperation with A. MAZNICHENKO and FRET efficiency measurements. 
 
3.1 Self-Assembly of Cyanuric Acid and Melamine  
 
Organization and aggregation of oligomeric biomolecules such as peptides and proteins play 
a crucial role in their functionality and stability.[95,96] Depending on the environment of such 
proteins, different folding states and assembly properties can be realized. Being highly com-
plex, this area of research proved to be fundamental for understanding the mechanistics of 
protein function.[97,98]  
Contrary to classic organic chemistry, these interactions happen on a reversible, non-cova-
lent level which makes protein folding and aggregation a versatile and complicated process 
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to study. Since hydrogen bond interactions are generally weaker than covalent bonds by 
tenfold, aggregation products are less stable. However, the formation of aggregation struc-
tures is reversible, leading to decomposition of non-favorable conformations.[99–101] Exam-
ples for these interactions are found in base pairing or the hemoprotein Nitrophorin 4 which 
even changes its conformation in dependency on the pH value.[102,103]  
Also, barbiturates, that are of biological and pharmaceutical relevance, show strong affinity 
to build up hydrogen bonds, resulting in supramolecular frameworks.[99,104,105] Another quite 
similar, yet interesting hydrogen bond network can be found in the so-called CA∙M lattice. 
First investigated by WHITESIDES et al., various possibilities of aggregation modes were 
found.[106,107] Utilizing the C-3 symmetry of cyanuric acid (CA) and melamine (M), the 
CA∙M network is built from multiple hydrogen bonds per building block (Figure 9).  
 
 
Figure 9: Equimolar mixtures of cyanuric acid and melamine are able to build up supramolecular structures. 
Here, a two dimensional network of the CA∙M lattice is shown with three present shapes, which can be defined: 
the hexameric rosette, the infinite crinkled tape and the infinite linear tape.[99]  
 
Thereby, three different macromolecular patterns were defined. The rosette motif consists 
of three melamine and three cyanuric acid moieties, aligned in an alternating fashion. With 
only six monomers, already 18 hydrogen bonds are formed, leading to a remarkably stable 
structure. Furthermore, the infinite, non-cyclic structures of the linear and the crinkled tape 
can be found in the CA∙M lattice.[99] However, especially hexameric assemblies like the ro-
sette are a well-known pattern in nature as it is for example found in apicomplexan adenosine 
triphosphate (ATP) synthase or in amyloid-β oligomers which may contribute to Alz-
heimer’s disease.[108,109]  
rosette crinkled tape 
linear tape 
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In terms of the CA∙M assemblies, WHITESIDES proposed two approaches to ensure the for-
mation of rosette structures (Figure 10). First, he named the concept of covalent preorgani-
zation. There, a C-3 symmetric spacer is used to link three melamine units covalently, bring-
ing three of six units already in close proximity to each other. Insertion of the cyanuric acid 
building blocks then leads to a facilitated rosette formation.[110] Second, he proposed the use 
of sterically demanding substituents in order to block defined sides of the melamine units. 
Thus, only specific areas are accessible for hydrogen bonding and aggregation.[107,111,112] 
Due to low solubility in organic solvents, X-ray measurements of single rosettes proved to 




Figure 10: WHITESIDE’s two proposed approaches to ensure rosette formation of an equimolar mixture of 
cyanuric acid and melamine. a) The concept of covalent preorganization: three melamine units are linked with 
a C-3 symmetric spacer in order to bring them in close proximity to facilitate insertion of cyanuric acid. b) The 
concept of peripheral crowding: Bulky substituents R are supposed to prevent other hydrogen bonding than the 
ones for rosette formation.[99]  
 
However, RANGANATHAN et al. obtained CA∙M rosette crystals by crystallization under hy-
drothermal conditions, revealing the dimensions of such rosettes (Figure 11 a). Furthermore, 
stacking of individual layers of rosettes was observed which build up a macromolecular 
channel structure (Figure 11 b). The cavity which is formed in the middle of the CA∙M ro-
sette was observed to have a diameter of roughly 4 Å.[14]   
More recent studies from MOTLOCH et al. utilized similar rosette structures to synthesize 
self-assembling hybrid cages.[114] During these experiments, barbiturate-pyridine (BA) was 
coordinated by palladium(II) or platinum(II) before adding it to modified melamine units in 
a)                                                                                  b) 
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chloroform. Cage formation was monitored and characterized by 1H-NMR, nuclear OVER-
HAUSER enhancement spectroscopy (NOESY) and diffusion ordered spectroscopy (DOSY), 
revealing the hydrodynamic radii of formed cages (Figure 12). 
 
 
Figure 11: a) Rosette dimensions obtained with hydrothermal condition crystallization and subsequent X-ray 
measurements. b) Three dimensional channel formation by stacking individual layers of rosettes.[14] 
 
Successful self-assembly could also be achieved by adding all single components in a one-
pot reaction. Furthermore, dual controllable disassembly could be shown by either introduc-
ing strong ligands which form more stable complexes with the metal ion or by adding a 
cyanurate moiety which forms more stable rosettes without the possibility of coordinating 
the metal.  
 
 
Figure 12: a) Structure of the rosette inspired hybrid cage by MOTLOCH et al. X depicts the used metal, in this 
case Pd(II) or Pt(II). Occurring cage formation was monitored via 1H-NMR. The characteristic rosette peak 
(barbiturate N-H) at approx. 14 ppm gives evidence of formed cages. Usage of Pd(II) (b), Pt(II) (c) and one-
pot self-assembly (d) was observed to successfully allow the formation of cages. Barbiturate related structures 
and peaks are marked in red, whereas melamine related details are encoded in blue.[114] 







δ(1H) / ppm 
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Regarding the attachment of these CA∙M building blocks to biomolecules, especially in the 
context of this thesis, recent research was done by KABATAS GLOWACKI from the 
DIEDERICHSEN group.[13] There, two β3-peptides were synthesized which contained three 
units of cyanuric acid and melamine, respectively (Figure 13). Adopting a 14-helix, they 
were designed in a way that the recognition units were stacked on top of each other upon 
helix formation, following positions i and i+3 (also see chapter 2.2). Analysis and character-
ization of formed rosette structures was observed via dynamic light scattering (DLS) meas-
urements and ESI-HRMS. In DLS, hydrodynamic sizes of 2.3-3.1 nm were found for pep-
tidic rosette aggregates, whereas monomeric peptides showed sizes of less than 1 nm. 
 
 
Figure 13: Deca-β3-peptides which were synthesized by KABATAS GLOWACKI for the organization as hex-
americ helix bundles in solution. Cyanuric acid related structures are marked in red, melamine structures in 
blue.[13] 
 
On the one hand, these results were perfectly aligned with theoretical estimations. On the 
other hand, further ESI measurements were carried out, finding evidence of threefold cy-
anuric acid and melamine adducts as expected in CA∙M rosettes (Figure 14). With these 
results, hexameric rosette formation according to the CA∙M lattice was confirmed to be 
adopted by 14-helices, leading to new possible approaches in the field of aggregation of 
β3-peptides. In this work, the rosette shaped helix bundle will be taken to the transmembrane 
level in order to create artificial self-assemblies within lipid membranes.  
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Figure 14: a) Schematic view on the formed helix bundle according to the CA∙M lattice by introduction of 
cyanuric acid and melamine into β3-peptides. Cyanuric acid related structures are marked in red, melamine 
structures in blue b) Mass spectrum of the formed rosette structure in sevenfold charge. Measured and calcu-
lated spectra are in perfect agreement, strongly supporting the assumption of aggregation.[13]   
 
3.2 Design and Synthesis of Transmembrane β-Peptides  
 
3.2.1 General Peptide Design 
 
In order to maintain comparability with previous work on transmembrane β-peptides from 
the DIEDERICHSEN group, this work is based on D-amino acids, which, in case of 14-helices, 
adapt a right-handed helix. Based on the results of PAHLKE and KABATAS GLOWACKI, β3-
peptides are able to form 14-helices in aqueous media without cyclic amino acids and can 
be aggregated by the use of cyanuric acid and melamine according to the CA∙M lattice.[13,74] 
Combining these findings with preliminary results on artificial transmembrane β-peptides, 
possibilities arise of assembling elongated transmembrane 14-helices which penetrate the 
membrane-water interface of lipid bilayers.[10,11] Similar work was done by PAHLKE in terms 
of near-membrane proton and calcium sensors based on the elongation of the standard trans-
membrane β-peptide model system with alternating sequences of β3-D-valine and β3-D-
lysine.[74] Since self-assembly of the pure transmembrane domain was excluded by 
STOLLBERG via FRET efficiency measurements, cyanuric acid and melamine were chosen 
as building blocks in order to enforce helix bundle formation out of transmembrane 14-hel-
ices.[11,12]  
a)                                                           b) 
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The transmembrane section of these peptides was adopted from STOLLBERG and consists of 
19 β3-D-valine units which are flanked by two β3-D-tryptophans and two β3-D-lysines with 
an additional C-terminal β3-D-lysine for fluorophore modification (Figure 15). The strongly 
14-helix promoting β3-D-valine units build up the hydrophobic core of the peptide which 
spans through the hydrophobic part of the membrane.[12,115,116] In addition, terminal flanking 
tryptophans are known to anchor peptides to the membrane-water interface, whereas lysine 
moieties enhance the solubility and therefore the handling of those compounds signifi-
cantly.[117,118] Since KABATAS GLOWACKI presented aggregation of 14-helices in aqueous 
solution, the WALP- and KALP-inspired transmembrane model systems were elongated and 
modified with cyanuric acid and melamine to achieve aggregation by hydrogen bond for-
mation in the water phase. Comparably, SCHNEGGENBURGER et al. developed nucleobase 
modified gramicidin A derivatives which assembled themselves by outer-membrane hydro-
gen bonds.[15]  
The self-assembly according to the CA∙M lattice relies on two hydrogen bond forming, aro-
matic building blocks. In general, aromatic side chains are known to interact with lipid mem-
branes, being able to affect membrane stability and properties.[119] Therefore, a three amino 
acid linker was introduced to the N-terminus of the transmembrane unit in order to prevent 
interactions between cyanuric acid or melamine units and the lipid membrane. Consisting of 
β3-D-valine, β3-D-lysine and β3-D-valine, the linker also promotes 14-helix formation, which 
is particularly important due to its positioning within the membrane-water interface. Then, 
cyanuric acid or melamine, respectively, were introduced by using a modified β3-D-lysine 
moiety, enabling the potential of aggregation without breaking helix symmetry. According 
to 14-helix specific stacking positions of i and i+3, two β3-D-amino acids were incorporated, 
followed by another cyanuric acid or melamine building block (Figure 15). In this work, the 
peptides were designed in a way that the rosette layers are shifted by one position (Figure 
16). Thereby, two aromatic residues are stacked on top of each other upon helix formation. 
Formed rosettes can be stabilized by hydrogen bonding as well as π-stacking of the aromatic 
building blocks. Based on this design, rosette formation of 14-helices in lipid membranes 
can be facilitated. The formation of artificial channel structures which can be formed due to 
the cavity, created within the rosette (Figure 16), was examined in subsequent assays. Also, 
C-terminal addition of an orthogonally protected β3-D-lysine motif enables the possibility of 
labeling the peptides. For initial analysis and proof of concept, 5(6)-carboxytetramethylrho-
damine (TAMRA) and 7-nitrobenzofurazan (NBD) can be incorporated into the peptides. 
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Figure 15: Chemical structure of cyanuric acid and melamine modified β-peptide transmembrane model sys-
tems. The C-terminal β3-D-lysine can be used to modify the peptides with a fluorophore, followed by the stand-
ard transmembrane system (green) and a short, three amino acid linker. A building block at position i with the 
next one being at position i+3 leads to stacking upon 14-helix formation. Cyanuric acid related structures are 
marked in red, melamine structures in blue. 
 
Carrying out FRET measurements, the proximity of both peptides can be determined in the 
lipid membrane to observe aggregation in the first place. However, determination of aggre-
gation states requires more advanced spectroscopical techniques like FCS.  
 
 
Figure 16: a) Schematic side view on the peptide alignment in a hexameric shape in the lipid membrane with 
two CA∙M rosettes. b) Top view on stacking CA∙M rosette-induced peptide aggregation, leading to a cavity 
within the helices. For a more comprehensive view, the transmembrane domain tilt of 16° is not considered in 
both figures. 
 
a)                                                                        b) 
1 
2 
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3.2.2 Synthesis of Artificial β3-D-Amino Acids 
 
Since β-peptides and most of the β-amino acids do not appear in nature, synthesis of β3-D-
amino acids was achieved from their commercially available α-analogues. Conversion into 
β3-D-amino acids was performed by the already established ARNDT-EISTERT-homologation 
(Scheme 2).[39] Hereby, the side chain and N-terminally protected amino acids were activated 
with triethylamine (1.10 eq) and isobutyl chloroformate (1.10 eq), followed by addition of 
diazomethane (2.00 eq). After nucleophilic substitution, a diazo ketone is formed as an in-
termediate in quantitative yield which was used without further purification. In a consecutive 
step, the diazo ketone was directly transferred to the respective β3-amino acid with silver 
benzoate (0.10 eq) and water in a WOLFF-rearrangement. Thereby, two literature-known 
methods were used. For the synthesis of Fmoc-β3-D-Val-OH, the diazo ketone was dissolved 
in a mixture of 1,4-dioxane and water (2:1, v/v) and after addition of silver benzoate, the 
mixture was irradiated with 460 W for 1 min in a domestic microwave oven (method B, see 
SOP4). For all other β3-D-amino acids, the respective diazo ketone was dissolved in a mix-
ture of THF and water (9:1, v/v), followed by the addition of silver benzoate and sonication 
for 2 h under the exclusion of light (method A, see SOP3). In both cases, final purification 
was achieved by precipitation in cold diethyl ether. 
 
 
Scheme 2: Synthetic route to obtain N-terminally protected β3-D-amino acids. Respective α-analogues were 
activated by triethylamine and isobutyl chloroformate to achieve backbone methylation by diazomethane. Re-
sulting diazo ketones were then transferred to final β3-D-amino acids by either using method A via sonication 
or using method B in a domestic microwave oven.[39]  
 
Utilizing the ARNDT-EISTERT-homologation, various amino acids could be synthesized in 
sufficient yields (Table 1). Ranging from 64 % to 93 %, the resulting β3-D-amino acids were 
then further modified or used in solid-phase peptide synthesis (SPPS). 
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Table 1: Respective yields of synthesized N-terminally protected β3-D-amino acids, resulting from the ARNDT-
EISTERT-homologation. 
 Yield / % 
Fmoc-β3-D-Val-OH (3) 77 
pNZ-β3-D-Val-OH (4)  64 
Fmoc-β3-D-Trp(Boc)-OH (5) 89 
Fmoc-β3-D-Lys(Boc)-OH (6) 79 
Fmoc-β3-D-Lys(Mtt)-OH (7) 78 
Boc-β3-D-Lys(Boc)-OH (8) 92 
Boc-β3-D-Lys(Cbz)-OH (9) 93 
 
In order to incorporate cyanuric acid and melamine into β-peptides, the CA∙M building 
blocks were attached to 14-helix promoting β3-D-amino acids. As already mentioned, this 
was achieved by modifying a β3-D-lysine moiety. For this purpose, a synthetic route based 
on KABATAS GLOWACKI was adapted.[13] The starting material, Boc-D-Lys(Cbz)-OH (10), 
remains stable under basic conditions. However, final substitution of the Boc-protecting 
group with a Fmoc-protecting group had to be executed in order to use building blocks in 
SPPS. First, the respective β3-D-amino acid 9 was synthesized via the ARNDT-EISTERT-ho-
mologation with a yield of 93 %. Subsequent palladium-catalyzed deprotection of the Cbz-
protected side chain was carried out by applying high pressures of hydrogen gas with 94 % 
yield. Thus, the resulting compound 11 was obtained with an overall yield of 86 % and was 
used as a key intermediate for both building blocks (Scheme 3). 
 
 
Scheme 3: Synthetic route to obtain key intermediate 11. First, the starting material 10 was converted to the 
respective β3-D-amino acid, followed by Cbz-deprotection via Pd-catalyzed hydrogenation. 
 
For the synthesis of the melamine functionalized building block, the now unprotected inter-
mediate 11 was converted to 12 via nucleophilic aromatic substitution by the use of NaOH 
(2.00 eq) and 2,4-diamino-6-chlorotriazine (1.20 eq) with a yield of 35 % (Scheme 4). Final 
  10                                                              9                                                               11 
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Boc-deprotection with excess of TFA and Fmoc-protection with NaHCO3 (1.50 eq) and 
Fmoc-OSu (1.50 eq) resulted in the final building block, Fmoc-β3-D-Lys(M)-OH (13), with 
a yield of 58 % over two steps. 
 
 
Scheme 4: Synthetic route to obtain the melamine functionalized building block 13. The unprotected β3-D-
amino acid 11 was treated with 2,4-diamino-6-chlorotriazine and NaOH to obtain the Boc-protected building 
block 12, followed by final deprotection and Fmoc-protection. 
 
The cyanuric acid modified building block was also synthesized by starting from key inter-
mediate 11 (Scheme 5). First, the side chain amine was converted to a hydroxyl group in a 
nucleophilic substitution by treatment with sodium nitroprusside (1.53 eq) and sodium hy-
droxide (3.08 eq) with a yield of 50 %. It has to be mentioned that higher yields are very 
unlikely for this reaction since the substitution reaction has to compete with the elimination, 
which also occurs under these conditions. The resulting, hydroxyl functionalized β3-D-amino 
acid 14 was further modified in an APPEL reaction under usage of tetrabromomethane 
(1.45 eq) and polymer-bound triphenylphosphine (2.10 eq). Yielding compound 15 with 
60 %, final side chain conversion was achieved with a yield of 24 % by using cyanuric 
acid (5.00 eq) and DBU (1.00 eq). Ultimately, the Boc-protected building block 16 was con-
verted to the final Fmoc-β3-D-Lys(CA)-OH (17) with a yield of 77 %. After adjusting 
KABATAS GLOWACKI’s synthetic route, further syntheses of these building blocks were exe-
cuted and kindly provided by B. WORBS. 
 
   11                                                                   12                                                                        13 
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Scheme 5: Synthetic route for the cyanuric acid functionalized building block 17. First, the side chain amine 
of key intermediate 11 was transformed into a hydroxyl group, followed by conversion to the bromo compound 
15. Then, nucleophilic substitution takes place, resulting in the Boc-protected building block 16. Similar to the 
melamine functionalized building block, changing the protection group to Fmoc results in the final building 
block 17.  
 
3.2.3 Synthesis and Labeling of Artificial β-Peptides 
 
Having all necessary β3-D-amino acids at hand, peptide synthesis was achieved by manual 
microwave-assisted solid-phase peptide synthesis (SPPS) according to the standard Fmoc-
protocol. First developed by MERRIFIELD, this method allows a progressive elongation of 
amino acid chains with ease (Scheme 6).[120,121] Based on a polymeric resin, amino acids can 
be attached stepwise while impurities and side products, which are not bound to the solid 
phase, can be separated by simple washing of the resin with organic solvent. For all peptides 
in this work, a low loaded NovaPEG rink amide resin with an occupancy of 170-200 µmol/g 
was used. After initial swelling in DMF for 2 h, the first amino acid was coupled. In general, 
β3-D-amino acid activation was achieved by using HATU (5.00 eq) and HOAt (5.00 eq) in 
DMF, followed by addition of DIPEA (10.0 eq) in NMP. Non-converted N-termini of the 
growing peptide chain were acetylated after every coupled amino acid with a mixture of 
Ac2O and NMP (1:4, v/v) in order to keep aborted sequences short, which facilitates later on 
purification procedures. Fmoc-deprotection was carried out by using DBU, piperidine and 
NMP (1:20:79, v/v/v) in two steps. For every amino acid, double coupling was performed 
which is especially important for the later stages of peptide synthesis (ten amino acids and 
  11                                                                     14                                                                      15 
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more), since the coupling efficiency significantly decreases with longer sequences.[122] Be-
tween every step of SPPS, multiple washing steps with MeOH and DMF were performed. 
Final cleavage of the peptide from the resin was achieved by using a cleavage cocktail, con-
sisting of TFA, TIS and ultra-pure water (95:2.5:2.5, v/v/v). In the case of automated SPPS, 
another coupling step with DIC (10.0 eq), Oxyma (5.00 eq) and DIPEA (0.50 eq) was added. 
Further experimental details can be found in chapter 6, SOP5 and SOP7. 
 
 
Scheme 6: Schematic procedure of solid-phase peptide synthesis. Fmoc-protected amino acids, which are 
bound to the resin (grey sphere), can be deprotected by the use of DBU, piperidine and NMP, resulting in an 
unprotected N-terminus. At this stage, amino acid coupling can take place by activation with HATU, HOAt 
and DIPEA. After amino acid coupling, non-reacted N-termini are acetylated with Ac2O in a capping step to 
prevent further side reactions. Once the final sequence is achieved, cleavage from the resin with TFA, TIS and 
water leads to the crude peptide. 
 
For the synthesis of 1 and 2, eight different amino acids were used. As necessary in SPPS, 
an orthogonal protecting group strategy was utilized by using N-terminally Fmoc-protected 
amino acids. Since deprotection of Fmoc can be carried out under basic conditions, respec-
tive side chains were protected with Boc protection groups, which can be cleaved under 
acidic conditions. For the initial, C-terminal β3-D-lysine moiety another side chain protecting 
group had to be chosen in order to deprotect and modify it selectively after coupling of the 
sequence. In this case, the Mtt-protection group was utilized, which is cleaved in slightly 
acidic conditions while maintaining orthogonality of the used protecting groups. Thereby, it 
can be selectively deprotected by using low amounts of acid, whereas Boc-protecting groups 
remain attached. According to this strategy, Fmoc-β3-D-Lys(Mtt)-OH, Fmoc-β3-D-
Lys(Boc)-OH, Fmoc-β3-D-Trp(Boc)-OH, Fmoc-β3-D-Val-OH, Boc-β3-D-Lys(CA)-OH, 
Boc-β3-D-Lys(M)-OH, Fmoc-β3-D-Lys(CA)-OH and Fmoc-β3-D-Lys(M)-OH were used to 
obtain both peptides. Since it is literature-known that deprotection of the Mtt-protecting 
group can also lead to Fmoc-deprotection, Boc-protected building blocks 12 and 16 were 
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used for final N-terminal coupling instead.[123] As already mentioned, initial analyses of ag-
gregation were planned to be executed by utilizing FRET measurements. Therefore, two 
fluorophores had to be attached to the sequence after deprotection of the C-terminal lysine 
moiety. Mtt-deprotection was carried out by using a mixture of TFA, DCM and MeOH 
(1:98:1, v/v/v) overnight (also see SOP8).  
To attach TAMRA, the dye (5.00 eq), DIC (10.0 eq) and Oxyma (5.00 eq) were added in 
DMF to the resin, followed by microwave-assisted heating to 65 °C for 1 h and excessive 
washing (Figure 17). However, in multiple attempts only traces of product could be observed 
and isolated after cleavage. Alternative reaction conditions like the use of PyBop and DIPEA 
or PyAOP and HOAt did not lead to product formation.   
 
 
Figure 17: Structures of C-terminally labeled CA∙M β-peptides. TAMRA-labeling was only achieved in traces, 
whereas NBD-labeling did not show conversion at all. TMD represents the transmembrane domain sequence. 
 
For the NBD labeled peptide, neither the use of NBD-Cl nor NBD-F were successful. Here, 
one can assume that NBD labeling is in general more challenging since a nucleophilic sub-
stitution takes place instead of amide bond formation as in the case of TAMRA labeling. 
Afterwards, test labeling without any CA∙M building blocks was performed in order to ex-
amine their influence on labeling reactions. Indeed, when labeling the transmembrane only, 
successful conversion was observed. This leads to the assumption that labeling of the pep-
tides interferes with the aromatic building blocks. According to this, the labeling strategy 
was changed to first labeling the transmembrane, followed by subsequent elongation with 
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the building blocks. In order to achieve this strategy, a different temporary, N-terminal pro-
tection group than Fmoc had to be used. Since the Fmoc-protecting group is also cleaved 
upon Mtt-deprotection, p-nitrobenzyloxycarbonyl (pNZ) was used instead. pNZ is another 
carbamate group which is cleaved in reducing conditions.[124] In order to incorporate this 
protecting group, a pNZ-β3-D-valine moiety was synthesized and added to the sequence 
(Scheme 7). Upon Mtt-deprotection, labeling with NBD was successful with the use of 
NBD-F (5.00 eq) and DIPEA (20.0 eq) in DMF. Subsequent pNZ-deprotection was achieved 
by adding 6 M SnCl2 and 1.6 mM HCl/dioxane in DMF. 
 
 
Scheme 7: Labeling of the pNZ-protected transmembrane domain. First, the Mtt-protecting group was cleaved, 
followed by NBD-labeling with NBD-F. pNZ deprotection lead to the free N-terminus, which was then further 
modified in SPPS. TMD represents the transmembrane domain. 
 
After thorough washing, the labeled and deprotected peptide 20 could be observed after test 
cleavage. However, further coupling of the CA∙M building blocks to the already labeled 
transmembrane domain was not successful.  
After not being able to pair C-terminal labeling with the building blocks, the Mtt-protected 
lysine moiety was attached to the N-terminus instead. On the one hand, labeling directly in 
proximity to the building blocks can enhance the interactions between the building blocks 
and the dye even more. On the other hand, locating the reaction site further away from the 
resin can also significantly increase coupling efficiency, gaining spatial accessibility. How-
ever, these attempts were also not successful in terms of product formation.  
Since FRET measurements would only show initial aggregation of the CA∙M modified 
building blocks in the first place, further labeling strategies were not executed. Additional 
possibilities would have been the attachment of the dyes directly to lysine moieties, followed 
by use in SPPS or use even more reactive dye species, like the TAMRA-NHS ester. In the 
case of NBD, a carboxylic acid linker could be introduced to the aromatic ring in order to 
obtain labeling via amide bond formation. Instead, peptides 1 and 2 were resynthesized and 
used without any labeling for further measurements, directly aiming towards the potential 
20 
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channel formation of aggregates with different assays. In addition, the pure transmembrane 




Figure 18: Chemical structure of the non-modified transmembrane domain 21, which was synthesized for the 
comparison with CA∙M modified peptides. 
 
For peptides 1, 2 and 21, successful synthesis was characterized by high resolution mass 
spectrometry (HR-MS) and CD spectroscopy (Figure 19). Both CA∙M modified peptides as 
well as the transmembrane domain itself show a zero crossing at 195-200 nm, with minima 




Figure 19: CD spectra of CA∙M modified peptides 1 and 2 (20 µM) as well as the transmembrane domain 21 
(50 µM) in MeOH at 25 °C. All peptides show minima at 190-195 nm with a zero crossing at 195-200 nm and 
maxima at 203-210 nm. All spectra were normalized according to GREENFIELD.[128]  
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3.3 Proton Translocation by Membrane-Incorporated 
 Transmembrane β-Peptides 
 
3.3.1 Proton Transport Assays 
 
Due to the attachment of fluorophores to peptides 1 and 2 not being successful, analysis 
methods other than FRET had to be performed. Therefore, direct addressing of potential 
channel activity of the two peptides was considered. Since the cavity of CA∙M rosettes is 
known to have a diameter of approximately 4 Å, these transmembrane peptides could enable 
transport or permeability of small ions across the membrane.[14] Characterization and prop-
erties of biochemical channels can be determined, for example, by conductivity or fluores-
cence measurements.[129,130]  
Just recently, SCHILLING et al. analyzed lugdunin, a thiazolidine peptide with antimicrobial 
activity.[131] By execution of two different fluorescence assays, it was shown that membrane 
activity is present in the form of proton translocation. On the one hand, dye leakage assays 
revealed that membrane disruption or destabilization is not induced by lugdunin. On the 
other hand, proton translocation was reported in a proton gradient experiment, based on the 
use of a pH sensitive pyranine dye. In order to analyze membrane activity of CA∙M modified 
peptides in terms of channel formation in lipid membranes, both experiments were executed 
with equimolar amounts of 1 and 2 as well as with the transmembrane domain 21 with dif-
ferent peptide to lipid (P/L) ratios. Both analyses were adapted and executed by D. RUPPELT 
from the STEINEM group.  
For the proton transport assay, POPC vesicles, filled with 5 mM HEPES buffer at pH 7.4, 
100 mM KCl and 500 µM pyranine, were prepared. Therefore, a stock solution of POPC in 
chloroform was transferred to a small test tube and dried under a nitrogen stream at 30 °C. 
After further drying overnight under reduced pressure, the resulting lipid film was rehydrated 
with a pyranine-buffer solution and extruded 31 times to obtain vesicles with a size of 
roughly 200 nm. Extravesicular dye which remained in the aqueous environment was re-
moved via size exclusion chromatography, followed by determination of the residual lipid 
concentration with a phosphate test (for further experimental details see chapter 6.3.3). Then, 
the lipid solution was transferred to a quartz glass cuvette and diluted with fluorophore-free 
HEPES buffer with a pH different from 7.4 to obtain a total lipid concentration of 50 mM. 
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According to this setup, a pH gradient between the inside of the vesicles and the outer solu-
tion was obtained before adding the peptides. Thereby, either buffer with pH 6.4 or 8.4 was 
used to dilute the vesicles, depending on whether proton influx or efflux should be moni-
tored. For example, when using pH 6.4 in the outer-vesicle environment, the influx of pro-
tons into the vesicle can be observed after addition and incorporation of channel proteins 
(Figure 20). Protons can translocate into the vesicle, resulting in a decrease of the inner-
vesicle pH. Present pyranine reacts to this change of environment with a decreasing fluores-
cence intensity.[132] In the case of dilution with pH 8.4, an increase of fluorescence intensity 
can be seen, indicating proton efflux. In both measurements, pyranine excitation was per-
formed at 458 nm with time-course recording of the emission intensity at 512 nm.[131]  
 
 
Figure 20: General view on proton transport assays. Vesicles with an inner pH of 7.4 are surrounded by HEPES 
buffer with pH 6.4. Upon addition in iPrOH or DMSO, channel peptides or proteins are incorporated into the 
membrane, leading to equilibration of the pH gradient. Resulting in a lower pH inside the vesicles, the pyranine 
emission intensity decreases. 
 
For the measurements of peptides 1 and 2 and also the transmembrane domain 21, vesicles 
were diluted in the cuvette to a volume of 792 µL. Then, stock solutions of peptides in iPrOH 
or DMSO with different concentrations were added to the vesicles, resulting in different 
peptide to lipid ratios. Thereby, 8 µL of peptide stock solution were used, keeping the or-
ganic solvent content at 1 %. As expected, proton influx in the case of an outer pH of 6.4 
can be observed by decreasing intensity of the pyranine dye (Figure 21). Furthermore, an 
effect of different peptide to lipid ratios on the emission intensity was observed. The P/L 
ratio of 1:1000 shows a less significant intensity decrease compared to 1:500 and 1:100. For 
an outer pH of 8.4, proton efflux results in an increase of the observed emission intensity. 
However, concentration dependent trends are not as prominent. The curves of P/L ratios of 
1:500 and 1:100 seem identical, meaning that the same amount of protons are translocated 
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during this experiment. This could be explained by the fact that the peptides do not fully 
incorporate into the membrane. Incomplete incorporation would mean that the actual peptide 
concentration is not consistent and therefore no concentration dependent assumptions can be 
made. Also p-xylene-bis(N-pyridinium bromide) (DPX), a pyranine quenching agent, was 
added after the efflux of protons, leading to a slightly decreasing intensity (see appendix). 
This indicates that there is only a minor amount of pyranine present in the outer medium. 




Figure 21: Proton transport assay results for CA∙M modified peptides 1 and 2. a) Using an outer pH of 6.4, 
protons rush into the vesicle upon peptide addition, leading to a decrease of intensity. b) An outer pH of 8.4, 
leads to a decrease of proton concentration in the vesicle, resulting in an increasing intensity. 
 
In order to evaluate the influence of the CA∙M building blocks on the proton assays, the 
results were compared with the pure transmembrane domain 21, applying the same assay 
with identical conditions. Surprisingly, the non-functionalized peptide shows the same ten-
dency in terms of proton translocation (Figure 22). Proton influx as well as efflux was mon-
itored with the proton transport assay. Also, the addition of DPX shows that no significant 
membrane destabilization takes place and that pyranine is not crossing the lipid membrane 
(see appendix). The results of both experiments suggest that the proton transport of synthe-
sized β-peptides can be assigned to the transmembrane part of the 14-helix and is not induced 
by the CA∙M aggregation. Therefore, further measurements focused on the analysis of the 
pure transmembrane peptide 21. Another observation after optimization of the transport as-
says was clear concentration dependency for P/L ratios in the range of 1:500 to 1:1000. 
a)                                                                                       b) 




Figure 22: Optimized proton transport assay results for transmembrane domain 21. a) Using an acidified outer-
membrane solution, protons rush inside the vesicles, lowering the pyranine intensity. b) Applying more basic 
conditions, protons move from the vesicle to the outer environment, increasing the pyranine intensity. 
 
 
3.3.2 Dye Leakage Assays 
 
In order to further test the effect of the peptide addition on the membrane stability, a dye 
leakage assay was performed. Since carboxyfluorescein is self-quenching in higher concen-
trations, it can be used to determine the leakiness of lipid membrane vesicles.[131,133] In ad-
dition, carboxyfluorescein is smaller than the pyranine dye. If the leakage of carboxyfluo-
rescein is ruled out, leakage of pyranine is also not expected.  
For this experiment, POPC vesicles were prepared, containing 20 mM HEPES and 100 mM 
carboxyfluorescein instead of pyranine. As long as the dye remains inside the vesicle, the 
high concentration leads to a low observable fluorescence signal. Once carboxyfluorescein 
passes the membrane, dilution in buffer leads to a significantly increasing fluorescence sig-
nal. To guarantee that the occurring signal is only contributed by leaking dye, the prepared 
vesicles were purified via size exclusion chromatography, removing any excessive dye in 
the outer buffer solution. After determination of the remaining phosphate concentration, a 
total lipid concentration of 50 mM was used for the measurements.  
Indeed, the initial assumption, that the membrane stays intact upon peptide addition, was 
confirmed, since the increase of carboxyfluorescein intensity for P/L ratios from 1:500 to 
1:1000 ranges from 1-3 % (Figure 23). Only in the case of 1:100, a slightly more prominent 
a)                                                                                       b) 
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leakage of 10 % can be observed.  
 
 
Figure 23: Dye leakage assay after addition of the transmembrane domain 21. P/L ratios ranging from 1:500 
to 1:1000 show low amounts (1-3 %) of leaking dye, indicating that no significant membrane destabilization 
takes place. Even in the case of a P/L ratio of 1:100, only 10 % of leakage can be observed. 
 
3.3.3 IR Measurements 
 
Since all preliminary work on transmembrane β-peptides was carried out by preparing lipid 
films with peptides, it remained to be shown that peptide addition to already formed vesicles 
leads to incorporation into the lipid membrane.[12,74] For this purpose, attenuated total reflec-
tance (ATR) measurements were performed by D. RUPPELT in order to prove that the results 
of the proton transport and dye leakage assays are caused by incorporated peptides. 
The so-called amide I vibration gives a signal ranging from 1600-1700 cm-1.[134] Majorly 
contributed by CO stretching, this signal can be used to detect present proteins and peptides. 
Here, the transmembrane domain 21 was added to a suspension of POPC vesicles and incu-
bated for 30 min. Non-incorporated peptides were removed via size exclusion chromatog-
raphy before spreading the vesicles on a germanium ATR-IR crystal. Thereby, multiple bi-
layers were obtained and examined (Figure 24). The POPC spectrum shows additional peaks 
in the amide I vibration range, the main peak being at roughly 1650 cm-1. According to 
KOZUCH, this region corresponds to either helical structures or to random coils.[135] However, 
the high stability of 14-helices leads to the assumption of helical structures within the POPC 
bilayers. With this, successful incorporation of the transmembrane domain was shown. 




Figure 24: IR spectrum of the transmembrane domain after incorporation into POPC vesicles and spreading 
bilayers on an IR crystal. The signal at 1650 cm-1, which can be seen in the enhanced view, can be assigned to 
CO stretching of the amide I vibration, indicating incorporated peptides. 
 
3.4 FRET-based Aggregation Studies of Transmem-
brane β-Peptides 
 
The results from the proton transport assay indicate that protons are passing the membrane 
upon peptide addition. Also transmembrane peptide incorporation was shown according to 
IR measurements. Since concentration dependency of the proton transport curves was ob-
served, one can assume that this translocation relies on selective and reproducible interac-
tions with potential channel structures being present. In order to examine the nature of these 
interactions, FRET measurements were utilized to determine the FRET efficiency of labeled 
transmembrane domains. With this assay, aggregation of the transmembrane peptides can be 
monitored. In previous work, STOLLBERG labeled these transmembrane domains with 
TAMRA and NBD for FRET efficiency measurements. There, no aggregation was found, 
since only a low amount of occurring FRET was observed.[12] The peptides were designed 
in a way that their fluorophores face the same direction upon antiparallel organization of the 
transmembrane domain. In order to investigate if the orientation of the fluorophore has an 
influence on the self-assembly, the here used peptides were all labeled N-terminally. If anti-
parallel aggregation occurs, they would face opposite directions after incorporation into lipid 
bilayers. However, major differences in both approaches are not expected since antiparallel 
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organization for β-peptides was only proven when nucleobases are present.[136,137] In the case 
of the transmembrane model system, the peptides are almost symmetrical except for the at-
tached fluorophore. Thus, there is no driving force for anisotropy with only the dipole mo-
ments of the peptides being able to contribute to a preferential orientation of organization.
  
For the execution for FRET measurements, three different transmembrane peptides had to 
be synthesized (Figure 25, for further details see section 6.4.3). Peptide 22 represents the 
TAMRA labeled transmembrane domain and peptide 23 the NBD labeled moiety, both con-
tributing to the measurement as the respective FRET pair. The acetylated peptide 24 was 
needed in order to keep the total peptide concentration consistent throughout all experiments. 
For labeling of the N-terminal lysine moiety, Boc-β3-D-Lys(Fmoc)-OH (25), which was 
kindly provided by N. HESSELBARTH, was used for selective deprotection at the labeling site. 
 
 
Figure 25: Modified transmembrane domain with an additional, N-terminal β3-D-lysine moiety. Usage of Boc-
β3-D-Lys(Fmoc)-OH leads to the possibility of orthogonal Fmoc deprotection and selective side-chain labeling. 
 
FRET measurements were performed by keeping the total lipid concentration at 2.5 mM and 
using a P/L ratio of 1:500. From there, the mole fraction χ of the NBD labeled peptide was 
kept at 0.50. The amount of TAMRA labeled peptide was varied from 0.00 to 0.50 in five 
steps. When necessary, the acetylated peptide was added to keep the total peptide concen-
tration constant in all measurements. The NBD dye was excited at 464 nm, recording the 
emission spectra from 500 nm to 650 nm (Figure 26). As expected, the NBD emission at 
530 nm decreased when higher amounts of TAMRA labeled peptides were present. Success-
ful FRET leads to the presence of a new TAMRA emission at around 570 nm, increasing 
with every measurement.  
 
22               23            24 
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Figure 26: FRET curves for varying amounts of TAMRA labeled peptide at 25 °C (a) and 60 °C (b). The 
concentration of NBD-labeled peptide was kept at χ = 0.50 while adding the acetylated peptide to keep the total 
peptide concentration constant. 
 
In order to distinguish between statistically occurring FRET and an aggregation-induced ef-
fect, the FRET efficiency was calculated. Therefore, the NBD emission at 530 nm for every 
respective measurement was divided by the emission at 530 nm with χ(TAMRA) = 0.00. 
According to this method, the aggregation state of glutamine modified transmembrane do-
mains was determined by STOLLBERG (ROST) et. al.[11] There, a FRET efficiency drop to 
60 % with same amounts of NBD and TAMRA labeled peptides (χ = 0.50 each) indicated 
that only monomers are present. However in the experiments of this work, the FRET effi-
ciency drops to roughly 36 % for the same measurement (Figure 27). According to 
STOLLBERG, this value is in the range of a monomer-trimer equilibrium, indicating clear 
signs of transmembrane domain aggregation.[11,12] In addition, almost the same behavior can 
be found for the measurement at 60 °C. In line with the proton transport assays, peptide-
peptide interaction was found which leads to the assumption that aggregation of these do-
mains is likely. However, the different outcome in comparison to STOLLBERG’s work is still 
unclear. Since the only difference was the N-terminal attachment of TAMRA, such major 
differences were not expected. An explanation could be that the orientation of the peptides 
plays a role for the aggregation of transmembrane β-peptides. If antiparallel aggregation was 
favorable, the sterical demand of the fluorophores could have an impact on the aggregation. 
In the setup of this work, the fluorophores would face different sides of the lipid membrane, 
inducing FRET while not being spatially constraint. In the case of STOLLBERG’s work, the 
fluorophores would face the same direction if antiparallel aggregation takes place. 
 
a)                                                                                  b) 
       SYNTHESIS OF TRANSMEMBRANE β-PEPTIDES FOR THE ORGANIZATION IN LIPID BILAYERS 
37 
 
Figure 27: FRET efficiency data for the transmembrane domain at 25 °C and 60 °C. Data were acquired by 
dividing the NBD emission F at 530 nm of respective FRET curves by the emission F0 at 530 nm without any 
TAMRA peptide present. The grey line depicts the FRET efficiency with no aggregation of the peptides ac-
cording to WOLBER et al. Statistical FRET efficiency data were kindly provided by STOLLBERG.[11,12] 
 
There, sterical hindrance would be more influential. In order to reveal more information 
about the anisotropy of the transmembrane domain aggregation, one could replace NBD and 
TAMRA with a FRET-pair that has a lower FÖRSTER radius. Then, one would only observe 
FRET if the fluorophores face the same direction. 
 
3.5 Conductance of Lipid Bilayers with Incorporated 
Transmembrane β-Peptides 
 
The previous shown experiments indicate that the transmembrane β-peptides indeed form 
aggregates in lipid membranes, being capable of triggering proton translocation. In addition 
to these experiments, the influence of the transmembrane domain on the conductivity of lipid 
bilayers was analyzed in collaboration with A. MAZNICHENKO from the POHL group.  
In various studies, the conductance of lipid membranes has been examined, especially with 
channel proteins being present.[129,139,140] There, single opening events as well as the change 
in conductivity after establishing a charge gradient over the membrane can be analyzed in 
order to determine possible channel activities of peptides and proteins.[141] In regard to this 
work, the transmembrane β-peptide 21 was also examined in terms of ion conductivity. A 
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change of conductivity upon establishing a pH gradient across lipid membranes would indi-
cate the presence of channel- or carrier-like aggregation of transmembrane β-peptides, con-
firming the previous results. Therefore, free-standing lipid bilayers were created on a small 
teflon septum (120-180 µm) by the Mueller method.[142,143] Buffers with pH 5.7 or pH 5.2 
were used, depending on the measurement. Bilayer formation itself was confirmed by optical 
observation as well as capacitance measurements. Then, the transmembrane peptides were 
added in iPrOH to both sides of the bilayers and incubated for 40 min at rt.   
For low concentrations of the transmembrane domain (25 nM), conductivity changes were 
measured and compared to a theoretical value, obtained by the NERNST potential (equa-
tion 3.1).[144] The experimental NERNST potential for a pH gradient of 0.5 is equal to the shift 
of the reversal potential, since there is no gradient of other ions present. Thereby, current-
voltage properties were monitored with an applied voltage ramp signal from -60 mV to 
+60 mV. In order to obtain an ion gradient across the membrane, β-alanine solution (3 M) 










Using the universal gas constant R, a temperature of 295.15 K, FARADAY’s constant F and 
transferring the pH values into proton concentrations according to [H+]=10-pH, the NERNST 
potential gives a value of 29.25 mV for this setup. Measurements were carried out without a 
proton gradient at pH 5.2 to obtain current-voltage curves, followed by the same measure-
ment with an applied pH gradient of 0.5 on one side of the membrane. The shift in reversal 
potential can be found by determining the shift of the intersections with the X-axis. First 
measurements were carried out by using 50 mM potassium chloride buffer as well as 0.1 mM 
MES (Figure 28). Comparison of the measurements with and without an applied pH gradient 
leads to a potential shift of 9.02 mV instead of the expected 29.25 mV. On the one hand, this 
could be explained by the peptides not being able to conduct ions across the membrane to a 
sufficient extent. On the other hand, the translocation of other ions than protons would also 
lead to such a result, since it was not considered in the calculation of the NERNST potential. 
In order to examine the latter, the buffer was first changed to 50 mM potassium sulfate buffer, 
excluding the potential translocation of chloride ions (Figure 28). However, this experiment 
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also leads to a similar potential shift of 13.66 mV, meaning that chloride ions are probably 
not conducted by the transmembrane peptides.  
 
 
Figure 28: Current-voltage characteristics of lipid bilayers with incorporated transmembrane β-peptide 21 
(25 nM) before applying a pH gradient. a) The use of 50 mM KCl buffer results in a potential shift of 9.02 mV. 
b) Changing the buffer to 50 mM potassium sulfate buffer leads to a shift of the reversal potential of 13.66 mV.  
 
Furthermore, 50 mM choline chloride buffer was used to analyze if potassium leads to dif-
ferent shifts in the potential. Indeed, for this measurement a potential shift of 28.44 mV has 
been found which is in agreement with the expected value of 29.25 mV (Figure 29). Accord-
ing to this result, one can assume that potassium ions contribute to the potential shift, there-
fore are also translocated by the used peptides. However, it has to be mentioned that the used 
concentration of potassium ions in the buffer (50 mM) is much higher than the concentration 
of the protons (~2-6 µM), which could be leading to a much more prominent influence on 
the measurement. In terms of potassium transport, the translocation could be induced by the 
applied charge gradient due to the addition of β-alanine solution. Surprisingly, in the meas-
urements with potassium containing buffer (Figure 28), the establishment of a pH gradient 
leads to an increased conductivity. This can be determined by the steeper slope of the cur-
rent-voltage curve, since a more prominent change of current can be observed with the same 
change of voltage. 
a)                                                                                    b) 
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Figure 29: Current-voltage characteristics of lipid bilayers with incorporated transmembrane β-peptide 21 
(25 nM) before and after applying a pH gradient. The shift in reversal potential was found to be 28.44 mV. 
 
In general, one would expect less conductivity for the measurements with a pH gradient. 
Assuming that the β-alanine and hydroxide ions are not able to cross the lipid membrane, 
there are less transportable protons present at pH 5.2 and pH 5.7 than at pH 5.2 on both sides. 
However, this phenomenon cannot be observed with no potassium present (Figure 29). Since 
more translocation seems to take place with less transportable ions, the assumption can be 
made that there could be a competitive behavior between protons and potassium ions.  
In general, the enhanced and channel-like conductivity with higher amounts of potassium 
ions in the solution could be possibly explained by electrostatic interactions between the 
carbonyl oxygen atoms of the peptides and the potassium itself, similar to KcsA, a potassium 
channel in Streptomyces lividans.[145] There, stabilization of the aggregates can take place by 
potassium ions, leading to higher conductivities of the membrane.  
In addition, measurements with application of a constant voltage of 150 mV were carried 
out. Here, higher concentrations of potassium ions (1 M KCl buffer) as well as peptides 
(100 nM) were used to observe the resulting current (Figure 30).   
Here, clear channel activity can be seen in up to three opening stages. In comparison to the 
other conductivity measurements, the rate of ion conduction seems to be significantly higher, 
resulting in distinct channel opening events. However, the exact influence of potassium ions 
and mechanism of ion conduction are still under discussion, since no active transport is ex-
pected with the present sequence. Also, channel activity was tested for lower pH values. 
Here, no opening events could be observed. It has to be mentioned that no potassium was 
present in the low pH measurement, so the exact reason for the absence of channels is not 
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clear. Subsequent experiments are currently executed by A. MAZNICHENKO. Further exami-




Figure 30: Time-resolved currents after applying a constant voltage of 150 mV to both sides of the membrane 
with the incorporated transmembrane domain 21 (100 nM) with 1 M KCl buffer. Resulting channel opening 
events can be observed in different stages. 
 
With these additional measurements, the selectivity of these channels can be determined. In 
order to gain more insight into the aggregation state of the transmembrane domain within 
lipid bilayers, FCS measurements have to be performed. There, after labeling of the trans-
membrane domain with Alexa488, the brightness of incorporated assemblies could reveal 
the aggregation state. Especially, measurements in dependency on the potassium concentra-









In the work of this chapter, transmembrane β-peptides were synthesized, inspired by exten-
sive preliminary studies in the DIEDERICHSEN group.[12,74,90] First, transmembrane peptide 
functionalization with cyanuric acid (CA) and melamine (M) was achieved by manual SPPS 
with an orthogonal protecting group strategy. Beforehand, all of the necessary β3-D-amino 
acids were synthesized in sufficient yields. CA∙M modified building blocks were synthesized 
according to KABATAS GLOWACKI with slight adjustments.[13] For FRET analysis, labeling 
attempts of the CA∙M modified transmembrane domains with TAMRA and NBD were per-
formed in different approaches. However, no fluorophore attachment could be obtained. 
Subsequently, the peptides were synthesized without any labels for a variety of assays, di-
rectly aiming at potential channel activities of the modified transmembrane domain. In pro-
ton transport assays, performed by D. RUPPELT, proton translocation was monitored upon 
addition of the modified transmembrane peptides. Surprisingly, comparison with the pure, 
non-modified transmembrane domain lead to the same results. Therefore, further measure-
ments were only performed with the standard model system. In addition to general proton 
transport, concentration dependency of the translocation on the used peptide concentration 
was observed. In order to gain insight in possible aggregation states of the transmembrane 
domain, which could enable this proton transport, FRET efficiency measurements were car-
ried out similar to STOLLBERG (ROST) et al.[11] A significant decrease in FRET efficiency 
was found in these experiments, indicating clear signs of peptide aggregation. Moreover, 
conductivity measurements of the transmembrane peptides were performed by A. MAZNI-
CHENKO. Applying a pH gradient across the membrane, low concentrations of peptides 
induced a change of conductivity. Both, protons and potassium ions, appear to be 
contributing to the translocation process. Higher peptide concentrations in high-salt buffer 
even showed clear channel opening events. Combining the results of all performed assays, 
clear indication of peptide aggregation was found as well as the ability to translocate protons 
and potassium ions across the lipid membrane. According to these results, the β-peptide 






4 Transmembrane β-Peptides as Near-
Membrane Molecular Rulers 
 
The outstanding properties of β-peptides, being precisely modifiable and building up highly 
ordered 14-helices, lead to various possible applications. In the following chapter, the rigid-
ity and stiffness of these 14-helices are used to introduce the concept of a peptidic molecular 
ruler. Two different 14-helices were synthesized, Atto643-labeled and, after incorporation 
into lipid bilayers, analyzed with grapheneMIET in regard to their distance to the substrate 
surface. The work of this chapter was performed in collaboration with A. SHARMA and is 
also published in Journal of Peptide Science.[146] 
 
4.1 FRET-based Molecular Rulers  
 
Since the introduction of the concept of FRET, it has been widely used to investigate biolog-
ical processes.[147,148] Thereby, the measurement of distinct distances is of special interest 
since it allows to determine structural and conformational conversions, e.g. of proteins and 
other biological macromolecules.[149–151] In numerous studies, FRET has been utilized to an-
alyze inter- and intramolecular distances and interactions, even in vivo.[152,153] For instance, 
the green fluorescent protein (GFP) has been used for live-imaging of cells by analyzing the 
energy transfer between two GFPs or one GFP and another fluorophore.[154] Thereby, mu-
tants of the wild type generate different spectroscopic properties, being highly suitable for 
FRET (Figure 31).[155] MIYAWAKI et al. took advantage of these GFPs by attaching two of 
them (BFP/GFP-pair or CFP/YFP-pair) to calmodulin and M13.[156] Calcium-modulated 
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protein (calmodulin) is a 148 residue, calcium-binding protein in the myosin light-chain ki-
nase (MLCK), being responsible for Ca2+ concentration monitoring, whereas M13 is a 26-
residue synthetic peptide which is binding to the calmodulin.[157–159] Upon addition of Ca2+, 




Figure 31: Excitation (a) and emission (b) spectra of modified GFPs: Y(ellow)FP, eGFP, C(yan)FP, Sapphire 
and B(lue)FP.[155] 
 
Thus, the distance between the FRET pair decreased, leading to a more prominent and effi-
cient energy transfer (Figure 32). After this proof of concept, the protein complex was ex-
pressed in HeLa cells. On the one hand, they could modulate the Ca2+ affinity of the protein 
complex by using mutants and on the other hand, they presented the FRET dependency of 
the Ca2+ concentration. With this, a powerful tool to measure free Ca2+ concentrations in 
compartments like the endoplasmic reticulum or the cytoplasm was created.[155,156] 
 
Figure 32: Calmodulin and M13 were N-terminally equipped with CFP and C-terminally equipped with YFP. 
Without present Ca2+, the protein complex remains unfolded and shows the CFP emission at 490 nm upon 
excitation at 440 nm. After the addition of Ca2+, protein folding occurs, leading to a significantly less distance 
between CFP and YFP. FRET can take place, resulting in emission at 530 nm. [155,156] 
a)                                                                   b) 
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Following a molecular ruler approach, ZHUANG et al. modified immobilized ribozymes with 
Cy3 and Cy5 dyes (Figure 33).[160] The 5’-end of a Tetrahymena ribozyme was hybridized 
to an oligonucleotide with the donor dye. The 3’-end was hybridized to a DNA fragment 
with the acceptor dye as well as a biotin moiety. Due to the biotin-streptavidin interaction, 
the protein complex could then be immobilized on a surface. Protein folding and unfolding 
was followed in terms of FRET. Upon unfolding, FRET revealed a distance of roughly 7 nm, 
whereas folding lead to distances between 1 and 2 nm. 
 
 
Figure 33: Schematic representation of the work of ZHUANG et al. The ribozyme is labeled with an oligonu-
cleotide-bound FRET donor (green star) at the 5’-end and with an acceptor at the 3’-end (red star). The DNA 
strand which is hybridized to the 3’-end also contains biotin (yellow square) to immobilize the complex on a 
streptavidin-coated (blue) surface. Upon folding, the distance between donor and acceptor decreases, leading 
to a more intense FRET signal.[160,161] 
 
However, since the application of FRET is limited to the FÖRSTER radius of the respective 
FRET-pair, long-range molecular rulers have been developed.[162] Applying plasmonic na-
noparticle-based surface energy transfer (NSET), it is possible to enhance the measurable 
distance between two probes up to 100 nm.[162,163] Other commonly used techniques to ob-
tain end-to-end distance distributions rely on X-ray scattering, NMR or EPR spectros-
copy.[17–19,164] Just recently, the concept of MIET and especially grapheneMIET has been 
introduced into the field of molecular rulers.[165,166] Thereby, distances up to 200 nm can be 
analyzed with remarkable resolution and accuracy.  
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4.2 Graphene-based Metal-Induced Energy Transfer 
 
In order to fully understand biochemical processes, spectroscopic and microscopic tech-
niques have been vastly examined throughout the last century.[165] Thereby, the characteris-
tics of fluorescent dyes are highly dependent on their direct environment. The impact of 
these surroundings can be for example seen in FÖRSTER resonance energy transfer spectros-
copy.[167,168] When matching donor and acceptor fluorophores are in proximity to each other, 
electromagnetic coupling between them occurs which leads to an energy transfer from the 
donor to the acceptor.[169] For this to happen, the emission spectrum of the donor has to 
overlap with the excitation spectrum of the acceptor fluorophore (Figure 34).[170] Since the 
transfer is inversely dependent on the distance of both fluorophores with the power of six, 
the technique is limited to distances of 1-10 nm.[147,171,172] However, numerous aggregation 
studies were performed utilizing this technique both in vitro and in vivo.[173–177]  
Moving on to microscopy techniques, one has to overcome the natural resolution limit which 
was first described by ABBE.[178] Techniques like interferometric photoactivated localization 
microscopy (PALM) and 4pi-stochastic optical reconstruction microscopy (STORM) use 
switchable fluorophores to surpass this resolution limit easily, reaching an axial accuracy of 
single fluorophores in the nanometer range.[179–181]  
 
 
Figure 34: a) A FRET pair is matching when the donor emission is overlapping with the acceptor excitation 
wavelength, shown for the example of Cerulean and Venus (fluorescent proteins). b) The JABLONSKI diagram 
representing the FRET effect. The donor is excited to an upper electronic state and emits excess vibrational 
energy radiationlessly. Afterwards, the emission and relaxation into the ground state is leads to energy transfer 
from the donor to the acceptor fluorophore by dipole-dipole-interactions. The acceptor also emits excess vi-
brational energy before emitting a photon and relaxing into the ground state.[182] 
a)                                                                                                b) 
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Another feasible method, which also generates axial localization in the nanometer range, is 
metal-induced energy transfer. In comparison to FRET, fluorescent probes transfer their en-
ergy to surface plasmons of a metal film which is coated onto a glass substrate, thereby 
acting as an acceptor molecule.[165] Due to the energy transfer, the fluorescence lifetime of 
the probe significantly decreases in dependence of distance to the metal film while the meas-
urement itself is only dependent on the orientation of one dye, not dependent on two dyes 
like in FRET. With this method, distances up to 200 nm can be detected and calculated from 
fluorescence lifetime data. Furthermore, the ENDERLEIN group presented a graphene-based 
MIET technique, using a single sheet of graphene instead of a metal film. It was shown that 
the axial accuracy was enhanced almost tenfold, being able to measure thicknesses of lipid 
bilayers with remarkable resolution.[166] Graphene sheets consist of pure carbon, arranged in 
a honeycomb structure with sp2 hybridization.[183] Similar to benzene, π electrons are delo-
calized throughout the lattice, with the 2px orbitals being perpendicular to the sheet plane.
[184] 
Thereby emerging optical and electronical properties have been widely examined in the past 
years.[185–187] The enhanced resolutional ability by performing MIET measurements with 
single sheets of graphene arises due to the significantly smaller coupling distance of the 
fluorophores with the graphene. In general, the achievable accuracy for the localization of 
fluorescent probes can be described depending on the interaction distance L and the number 
of detected photons N with 𝐿/√𝑁. With this proportional correlation, the resolution is im-
proved tenfold with the same amount of detected photons, assuming that L is decreased ten-
fold when using graphene instead of metals in MIET.[166] Experimentally, in grapheneMIET 
measurements the fluorescent probe is placed above a single sheet of graphene, which is 
surrounded by a SiO2 spacer and a glass substrate (Figure 35). Assuming the fluorophore to 
behave like an ideal electric dipole emitter, one can solve MAXWELL’s equations to obtain 
the radiative emission power S(α, z0), being dependent on the dipole distance z0 to the surface 
and the orientation α.[165,166] Since the fluorescence lifetime τf is inversely proportional to the 







Փ𝑆(𝛼,  𝑧0) + (1 − Փ)𝑆0
 (4.1) 
 
Thereby, τ0 describes the free-space fluorescence lifetime and⁡Փ denotes the fluorescence 
quantum yield, which has to be considered for non-ideal fluorophores. S0 is the emission 
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power in free-space (without graphene) which is given by 𝑆0 = 𝑐𝑛𝑘0
4𝑝2/3 with c being the 
speed of light in vacuum, n is the refractive index, k0 the wave vector and p the amplitude of 
the dipole moment. Regarding the orientation α, in the case of examining peptides, it can be 
assumed that fluorescent probes are rotationally diffusing on the substrate due to the carbon 
linker of respective dyes. This diffusion is expected to be much faster compared to the fluo-
rescence lifetime, meaning that the orientation of the fluorophore can be averaged. The emis-
sion power can be expressed by distributing the total emission power into perpendicular 










According to this, MIET curves can be calculated to give the distance of the fluorophore to 
the surface, depending on the fluorescence lifetime of the dye (Figure 35). 
  
 
Figure 35: a) GrapheneMIET setup with an emitter being placed above a single sheet graphene which is sur-
rounded by a SiO2 spacer and a glass substrate. b) A general view on the relative fluorescence lifetime depend-
ing on the distance z0 to the sheet of graphene for quantum yields ranging from Փ =0.1 to Փ =1.0 as well as 
either parallel or perpendicular oriented emitters.[166] 
 
In the context of near-membrane processes, one can clearly see that the application of MIET 
or grapheneMIET on single molecules can come in very handy to determine axial localiza-
tion of fluorescent probes. For example, CHIZHIK et al. presented an approach of MIET im-
aging of the basal lipid membrane of living cells.[188] MDA-MB-231 cells were monitored 
a)                                                                                        b) 
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while moving across a surface with an axial resolution of 3 nm. Shortly after, the concept of 
MIET was applied on single molecules, determining the distance of Atto655 dyes on differ-
ent heights of SiO2 spacers in remarkable accuracy in the low nanometer range.
[189] Regard-
ing grapheneMIET experiments, supported lipid bilayers (SLBs), DLPC and DOPC, were 
labeled with Atto655 and the respective lifetime data as well as end-to-end distances were 
measured and calculated.[166] Comparing these results with the literature,  the axial accuracy 
of MIET could be improved to be in the ångström region by using graphene-based MIET 
imaging. Based on these promising possibilities, grapheneMIET fulfills all requirements to 
study processes that are dependent on the distance to lipid membranes.   
 
4.3 Design and Synthesis of Atto643-labeled Transmem-
brane β-Peptides 
 
The near-membrane environment delivers a fascinating field of research, providing the lo-
cation for lots of essential biological processes.[190] Especially, distance-dependent sensorial 
properties across the membrane surface are of interest, since a lot of processes, e.g. SNARE 
fusion, are linked to near-membrane ion concentrations like calcium or protons.[20,191–193] 
Also, diseased tissue displays an increased acidic surface compared to its surroundings 
which delivers an interesting approach for the use of near-membrane pH sensors.[194]   
However, determination of those parameters can be quite inaccessible. Bulk measurements 
can only reveal information across the overall environment, resulting in averaged parame-
ters. Regarding lipid membranes, charges of the lipid head groups often play an important 
role for the near-membrane environment and function.[195] For example, negatively charged 
head groups can cause an increased cation concentration in the proximal aqueous phase, 
comparable to the electrical double layer.[196–199]  
In order to understand the mechanics and properties of the near-membrane environment, 
defined spatial placement of probes is key.[190,200] In fact, distance-dependent analysis of the 
membrane environment can be used to obtain a deeper insight into its function and proximal 
ion concentrations, which are contributing to vital processes.[16,20] End-to-end distances as 
well as distance-dependent interactions have been well examined over the course of the last 
decades. For instance, FRET played an immensely important role in these studies, being a 
powerful tool to investigate biological processes (also see chapter 4.1).  
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Measurements of near-membrane ion concentrations were already examined in numerous 
studies.[201,202] However, when based on membrane-bound ion sensors, these sensors are lim-
ited to the direct surface of the membrane. Therefore, the need for a molecular ruler arises 
which can be used for placing probes in distinct distances in regard to the lipid membrane. 
Requirements for this type of ruler can be described as the following:   
First, the ruler needs to be structurally rigid, maintaining its straight and well-examined 
structure in all present environments. Second, when talking about near-membrane measure-
ments, it has to have a defined length with a fixed position in regard to the membrane. With 
this, positioning of probes as well as the height in respect to the membrane can be controlled. 
Third, in order to use the ruler for a various number of experiments, it has to be adjustable 
in length to analyze different membrane distances. Finally, a molecular ruler has to be easily 
modifiable. Probes need to be attached to the ruler with ease to guarantee versatile applica-
tions. 
Based on these requirements, 14-helices, as previously used for the organization in lipid 
membranes (see chapter 3), provide an excellent model system for such a ruler. As already 
mentioned, 14-helices are highly rigid in the hydrophobic environment.[8] According to the 
studies of PAHLKE, these helices can also be formed in aqueous solutions if a certain number 
of amino acids in the sequence is exceeded.[61,74] Also, 14-helices are well understood in 
their structure, delivering a defined helical pitch of roughly 5 Å with a rise per residue of 
1.56 Å.[65,66] Transmembrane 14-helices can therefore be designed in a way that they accord 
to the membrane thickness and can then be elongated while providing full knowledge about 
their helical length. Especially, N-terminal modifications with sensors or other functional 
groups can be easily realized on-resin with numerous known methods.[203–206] As one can 
see, all established criteria for molecular rulers can be fulfilled by β-peptide 14-helices, pro-
moting them for the use in near-membrane investigations.  
In order to show a proof of concept, two respective transmembrane 14-helices with an N-ter-
minal β-alanine for labeling were synthesized (Figure 36). The first peptide 26, being shorter 
in length, consists of the β-alanine unit and the in chapter 3 described standard transmem-
brane domain which is built from 19 consecutive β3-valines, flanked by two β3-tryptophan 
and two β3-lysine moieties each. Peptide 27 represents a sequence elongation by two turns 
(six amino acids) with an alternating sequence of β3-valine and β3-lysine. Since these two 
turns are representing the extra-membrane elongation after incorporation of the peptide into 
a DOPC bilayer, it has to be ensured that they also form a 14-helix in the presence of the 
aqueous medium. Therefore, the elongation design is chosen to be similar to the studies of 
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PAHLKE.[74] There, the same alternating sequence in a nona-β-peptide clearly indicated to-




Figure 36: Structural design of synthesized 14-helices 26 and 27. The transmembrane part (green) consists of 
19 β3-valine units, which are flanked by two β3-tryptophans and two β3-lysines each. Sequence elongation of 
27 was achieved by introducing an alternating sequence of β3-lysine and β3-valine. For the use as molecular 
rulers, both peptides were modified with an N-terminal β-alanine which was further equipped with Atto643 
(cyan star).[146] 
 
According to 14-helix dimensions and considering the 16° helical tilt of transmembrane β-
peptides in DOPC, 26 is calculated to have a height of 4.42 nm in regard to the bottom leaflet, 
whereas the height of 27 is calculated to be 5.36 nm (Figure 37).[10,146] Thereby, it is assumed 
that 27 is also tilted by 16°.  
For analyzing the functionality of a 14-helix molecular ruler, the advantages of precise and 
accessible grapheneMIET measurements were utilized in cooperation with A. SHARMA from 
the ENDERLEIN group. Therefore, the peptides were N-terminally labeled with a fluorophore 
in order to facilitate energy transfer from the dye to the graphene surface. After consideration 
of the fact that the dye has to be mono-exponential, indicating only one excited state, differ-
ent dyes were tested. Since other synthesized peptides with carboxyfluorescein or TAMRA 
labeling turned out to be not suitable for the use of grapheneMIET, Atto643 was used in-
stead. Atto643 is a mono-exponential and pH independent dye, which has already utilized in 
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Figure 37: Schematic view on the concept of 14-helical molecular rulers. Two peptides were synthesized, 
consisting of the transmembrane domain and an Atto643 dye (cyan star). After incorporation into DOPC bi-
layers with a thickness of approximately 5 nm, the respective dyes are in defined distances in regard to the lipid 
membrane. Thereby, the elongated peptide 27 shows a greater distance from the bottom leaflet compared to 
peptide 26. According to the 16° tilt of 14-helices in DOPC membranes, this results in a theoretical height 
difference of approximately 9 Å.[10,146] 
 
Peptide synthesis was achieved via manual SPPS according to chapter 3.2.3. Based on 
NovaPEG rink amide resin with an occupancy of 200 µmol/g, 26 and 27 were synthesized 
by using orthogonally protected β3-amino acids (5.00 eq) to guarantee full compatibility with 
the Fmoc-strategy. Therefore, Fmoc-β3-D-Val-OH, Fmoc-β3-D-Lys(Boc)-OH and Fmoc-β3-
D-Trp(Boc)-OH were synthesized via the ARNDT-EISTERT-homologation, starting from their 
respective α-analogues.  
After N-terminal coupling of Fmoc-β-alanine for both peptides, microwave-assisted Fmoc-
deprotection was performed with a solution of NMP, piperidine and DBU (79:20:1, v/v/v). 
The resulting unprotected N-terminus was then labeled with Atto643 in order to make the 
peptides accessible for grapheneMIET measurements. Therefore, adapting the recommen-
dations from ATTO-TEC GMBH, Atto643-NHS ester (0.81 eq) was dissolved in dry and 
amine-free DMSO (400 µL) and added to the resin.[210] Activation took place by adding 
DIPEA (4.00 eq), followed by microwave-assisted heating to 37 °C for 2 h. Afterwards, the 
resin was mechanically shaken overnight at 37 °C.[146] The labeled resin was then washed 
with DMF and MeOH (15 × 5 mL) and cleaved with a mixture of TFA/H2O/TIS (95:2.5:2.5, 
v/v/v). Evaporation of the solvent in a nitrogen stream, precipitation in cold diethyl ether and 
further purification via HPLC lead to 26 and 27, respectively.  
Both peptides were verified via mass spectrometry and their capability of 14-helix formation 
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was shown by CD spectroscopy (Figure 38). According to literature, these helices show 
minima at roughly 195 nm, zero crossings at 200 nm and maxima at 210 nm, indicating suc-
cessful right-handed 14-helix formation.[63,126,127] 
 
 
Figure 38: CD spectra of 26 (~8 µM) and 27 (25 µM) in MeOH at 25 °C. 26 shows a minimum at 193 nm with 
a zero crossing at 196 nm and a maximum at 210 nm. 27 shows a minimum at 191 nm, a zero crossing at 
199 nm and a maximum at 208 nm. Both spectra were normalized according to GREENFIELD.[128]  
 
4.4 grapheneMIET Measurements of Atto643-labeled 
Transmembrane β-Peptides 
 
After successful synthesis and characterization of the Atto643-labeled peptides, graphene-
MIET measurements were performed in collaboration with A. SHARMA. Peptides 26 and 27, 
separately, were incorporated into lipid bilayers with a peptide-to-lipid ratio of 1:25000. 
Lipid bilayers were obtained by spreading giant unilamellar vesicles (GUVs) onto the gra-
phene-containing glass substrate from GRAPHENE LABORATORIES INC. (New York, USA). 
GUV formation was performed by heating a mixture of peptides in methanol and DOPC in 
chloroform under reduced pressure on an aluminum electrode to 30 °C. After complete dry-
ing, a thin lipid film was gained which was rehydrated with 500 µL of 300 mM sucrose so-
lution. For 3 h, the solution was treated with an alternating current (15 Hz, 1.6 V peak-to-
peak voltage). Then, it was further treated with 8 Hz for 30 min. Finally, 500 µL of PBS 
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buffer was added.   
Since the orientation α of the Atto643 dye is also contributing to radiative emission power 
S(α, z0), a random orientation was assumed after analyzing GUVs with polarization-resolved 
fluorescence imaging (Figure 39). After determination of the fluorophore orientation, 
spreading of SLBs onto the graphene substrate was achieved by adding the GUV solution 
after 30-fold dilution to the surface. Formed bilayers were washed with PBS buffer after 1 h, 
carefully but thoroughly. Thereby, incorporated peptides can align either with the fluoro-
phore pointing above the membrane, penetrating the aqueous medium, or pointing below the 
membrane, interfering with the SiO2 spacer. 
 
 
Figure 39: Linear polarized fluorescence imaging was utilized to obtain a GUV image to confirm randomly 
oriented fluorescent dyes.[146] 
 
A schematic view on the setup can be seen in Figure 40. Here, 26 and 27 are embedded into 
the membrane and height differences in regard to the substrate surface can be seen. However, 
measurements were carried out with only one species of peptides being present in the lipid 
membrane at a time. 26 and 27 were prepared and measured in separate membranes. As 
already mentioned, the concept and β-peptide design relies on the outstanding stability of 
14-helices. Since they are able to form rigid structures in organic and aqueous solutions, they 
can be reconstituted into lipid bilayers with ease.[10,11,74] Transmembrane 14-helices, devel-
oped by STOLLBERG, showed a 16° helical tilt when being reconstituted into DOPC lipid 
membranes.[10] Due to the rigidity of those helices, this tilt can also be assumed for elongated 
peptides. Taking the tilt and literature-known dimensions of the 14-helix into account, one 
can calculate the maximum distance of the peptide termini to the surface after incorporation 
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into the lipid membrane. For the labeled transmembrane domain 26, a height of 4.42 nm is 
expected, whereas the height of 27 increases to 5.36 nm.  
 
 
Figure 40: Experimental sample setup for MIET measurements of DOPC lipid bilayers with incorporated 
Atto643-labeled 14-helices. A single sheet of graphene is located between a 10 nm SiO2 spacer and a glass 
substrate. GUVs, containing either 26 or 27, were spread onto the substrate to obtain lipid bilayers. Height 
differences of the Atto643 fluorophores (cyan stars) in regard to the surface were then determined with gra-
pheneMIET, performed by A. SHARMA. In this figure, only one direction of peptide orientation is consid-
ered.[146] 
 
The free-space lifetime of peptide-bound Atto643 in solution (4 ns) was determined by time-
correlated single photon counting (TCSPC) and using a given quantum yield (0.62) and the 
free-space lifetime of non-bound Atto643 (3.5 ns), the quantum yield of peptide-bound 
Atto643 was calculated to be 0.71. Considering a bilayer thickness of around 5 nm, a refrac-
tive index of 1.46 of the bilayer, a graphene layer thickness of 0.34 nm and its complex 
refractive index of 2.77 + 1.42i as well as a SiO2 spacer thickness of 10 nm with an refractive 
index of 1.46, the grapheneMIET curve was calculated (Figure 41).  
After reconstitution of Atto643-labeled peptides into GUVs with a peptide to lipid ratio of 
1:25000, the lipid was spread on the graphene-coated substrate to obtain a lipid bilayer. An 
area of 25 µm² was examined with a confocal laser scanning microscope (CLSM) in order 
to obtain fluorescence decay curves (Figure 41). The data was acquired from three different 
areas in three independent samples. After fitting with a decay function, the obtained lifetimes 
were then transferred into distances using the grapheneMIET curve. 
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Figure 41: a) Obtained fluorescence decay data by using CLSM for 26 and 27. Measured data are depicted in 
blue and yellow, respectively, whereas triple exponential fits are given in red and green. b) Calculated gra-
pheneMIET curve after consideration of thicknesses and refractive indices of the lipid membrane, a single 
sheet of graphene and the SiO2 spacer.[146]  
 
Using the grapheneMIET curve, measured lifetimes of peptide-bound Atto643 can be con-
verted into heights in regard to the surface. Thereby, two distances for each peptide can be 
found, one with the dye pointing above the bilayer and one with the dye pointing below the 
bilayer. For 26, distances of 2.9 ± 0.3 nm and 8.4 ± 0.1 nm can be found, leading to an end-
to-end height of 5.5 ± 0.4 nm. 27 shows heights of 1.70 ± 0.03 nm and 7.90 ± 0.27 nm, re-
sulting in a height difference of 6.2 ± 0.2 nm.  
In the case of dyes pointing below the membrane, a difference between 2.9 nm and 1.70 nm 
seems quite large but could be theoretically explained by the different peptide lengths. Since 
27 is elongated, it is closer to the substrate surface, leading to decreased distances in the 
measurement. However, the SiO2 is directly underlying the membrane bilayer, interacting 
with bottom-oriented peptides and dyes. Therefore, one would expect only minor differences 
in the cases of 26 and 27. Surface roughness of the SiO2 spacer can potentially play a role 
since varying surface thicknesses can lead to different experimental data. Therefore, end-to-
end distances or heights of the peptides were calculated.  
In comparison to the estimated values (Table 2), the measured values appear larger which is 
most probably explained by the dimensions of the Atto643 dye and its three methylene unit 
linker. The same phenomenon was observed in previous grapheneMIET studies.[165,166]  
 
a)                                                                                             b) 
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Table 2: Comparison between estimated and experimental determined end-to-end height differences of 26 and 
27. 
 Estimated height / nm Experimental height / nm 
26 4.42 5.5 ± 0.4 
27 5.36 6.2 ± 0.2 
 
Peptide 26, being the non-elongated transmembrane domain, shows a height of 5.5 ± 0.4 nm. 
This is in perfect agreement with the DOPC bilayer thickness of 5.5 ± 0.4 nm which was 
also investigated with grapheneMIET.[166] 27 shows an end-to-end difference of 6.2 ± 0.2 nm 
which is increased compared to 26. According to the defined distance of 27, one can assume 
that it is successfully incorporated into the lipid membrane and remains its 14-helix rigidity 
throughout the change of medium from the membrane to the aqueous buffer. Distinct differ-
ences in the end-to-end heights of 26 and 27 also indicate that a use as molecular rulers is 




In the work of this chapter, two transmembrane β-peptide 14-helices were designed, synthe-
sized with manual SPPS and characterized via CD spectroscopy and mass spectrometry. 
Differing in length, they were labeled with Atto643, which shows perfectly suitable spectro-
scopic properties in grapheneMIET measurements. On the one hand, the use of this highly 
precise technique enabled the determination, whether 14-helices are capable of being func-
tionalized as molecular rulers. On the other hand, several other open questions could be ad-
dressed by the performed measurements. After incorporation of the labeled peptides into 
DOPC GUVs, they were spread on a substrate surface to obtain SLBs. In cooperation with 
A. SHARMA from the ENDERLEIN group, the labeled transmembrane domain 26 was deter-
mined with an end-to-end height of 5.5 ± 0.4 nm which perfectly agrees with preliminary 
analyses of DOPC bilayers with grapheneMIET.[166] The by two turns elongated peptide 27 
is calculated to have an end-to-end height of 6.2 ± 0.2 nm, agreeing with theoretical estima-
tions.  
Regarding the distinct height differences compared to the substrate surface, a proof of con-
cept was established which enables the use of transmembrane 14-helices as molecular rulers. 
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Following up on these measurements, various sensorial probes can be attached to the easily 
modifiable 14-helices in order to investigate the near-membrane environment. Also, it was 
shown that elongated β-peptide 14-helices, which surpass the membrane-water interface, 
successfully incorporate into DOPC membranes. Finally, helical persistence for 14-helices 






5 Summary and Outlook 
 
The severe importance of protein-protein and protein-lipid interactions in living organisms 
lead to extensive research in order to understand and learn from biological processes.[211–213] 
Especially in the last decades, biochemical phenomena caught scientist’s attention. The ag-
gregation of proteins and peptides plays a crucial role in their biochemical function.[96] Since 
the size and complexity of these macromolecules hinder the accessibility of conclusive stud-
ies, different peptidic model systems, like the WALP peptides, have been developed. Sim-
plification of these complicated structures enables specific targeting of research towards dis-
tinct areas or functional sites of a protein. Artificial model systems, consisting of β-amino 
acids, have been studied in the last years. Developed by STOLLBERG, a transmembrane model 
system has been established which is based on the well examined 14-helix.[10] Relating to 
her work as well as KABATAS GLOWACKI’s aggregation studies of β-peptides with incorpo-
rated cyanuric acid (CA) and melamine (M), this work dealt with the assembly of transmem-
brane β-peptides according to the CA∙M rosette.[11,13]  
First, transmembrane 14-helices with cyanuric acid or melamine modified β3-D-lysine moi-
eties were synthesized (Figure 42) in order to organize the peptides within lipid membranes. 
Successful synthesis as well as helix formation were confirmed via ESI-MS measurements 
and CD spectroscopy. For the analysis of non-labeled peptides, different assays were per-
formed which directly aimed towards potential aggregation and channel or carrier functions 
of the incorporated peptides. First, a proton transport assay, which can monitor proton influx 
and efflux due to the presence of a pH dependent pyranine dye, was performed by D. 
RUPPELT. Indeed, proton translocation was observed after incorporation of 1 and 2 into 
POPC vesicles. However, same experiments with the pure transmembrane domain 21 
showed similar behavior in terms of proton translocation. Optimization of the experiment 
revealed concentration dependency of the proton transport on the used amount of peptide. 
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Figure 42: Synthesized transmembrane 14-helices with incorporated cyanuric acid and melamine for the or-
ganization as helix bundles in lipid membranes. 
 
With these results in hand, one can assume that the translocation is based on the transmem-
brane domain itself and not on CA∙M-induced aggregation of peptides. Furthermore, a dye 
leakage assay was performed in order to exclude false positive results, for example due to 
bursting vesicles. There, only 2-3 % of self-quenching dye were released from vesicles after 
peptide addition.  
Peptide concentration dependency as well as intact vesicles indicated towards selective and 
systematic interactions in the lipid membrane. For this proton translocation to happen, pep-
tide assemblies are needed which was analyzed in subsequent FRET measurements. Trans-
membrane domains were labeled with TAMRA and NBD, a common FRET pair in peptide 
analyses. In order to keep the total peptide concentration constant throughout the measure-
ments, an acetylated transmembrane domain was also synthesized. FRET efficiency was 
monitored and showed a decrease in intensity, significantly more than compared to the sta-
tistical FRET, indicating successful aggregation of transmembrane peptides. Thus, two dif-
ferent assays were performed which indicated peptide-peptide interactions in the lipid mem-
brane, being responsible for ion translocation.   
More physiochemical analyses of 21 were executed by A. MAZNICHENKO via membrane 
conductivity measurements. Free-standing lipid membranes were incorporated with the 
transmembrane domain while measuring the change of conductivity after applying a voltage 
ramp from -60 to +60 mV. By comparison with the NERNST potential, the change of the 
reversal potential showed that incorporated transmembrane domains indeed are able to allow 
ion translocation. However, not only protons but also potassium ions are contributing to this 
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that potassium has a crucial role for the activity and stability of such carrier or channel struc-
tures. In addition, channel-like behavior was found for higher concentrations of peptides and 
potassium buffer. Single opening events were monitored by applying a constant voltage of 
150 mV, indicating a much higher rate of translocation. However, the mechanism of the 
peptide-peptide interactions and the translocation of the ions remains unclear. In case of 
channel opening events, the question arises if the carrier or channel formation is induced by 
the higher concentration of peptide or the higher concentration of potassium buffer. Since 
the peptide concentration is only enhanced by four-fold in comparison to the other measure-
ments, the high potassium concentration seems to be key for the structures to form, poten-
tially stabilizing the formed aggregates. Further analyses have to be performed in order to 
characterize these channels, especially regarding the dependency on the potassium concen-
tration and the aggregation state of the transmembrane domain. Common potassium chan-
nels consist of a quantity of two, four or six transmembrane helices.[145] In this case, an ag-
gregate of two transmembrane β-peptides can be excluded since the FRET efficiency (see 
chapter 3.4) was significantly higher than for a dimer which was calculated by STOLLBERG 
(ROST) et al.[11] Further analysis on the aggregation state, next to FRET efficiency measure-
ments, have to be carried out, for example via FCS, using a labeled transmembrane domain. 
In addition, the comparison between the transmembrane domain and the CA∙M modified 
peptides would be interesting. Then, one could determine if the incorporation of such build-
ing blocks enhances the channel formation in terms of ion translocation efficiency. Addi-
tionally, the selectivity towards other small cations like magnesium or sodium has to be 
determined. A graphical overview of the results of this topic can be found in Figure 43.  
The second part of this thesis dealt with a novel transmembrane β-peptide-based molecular 
ruler in order to investigate the near-membrane environment. The spatial positioning of mo-
lecular probes such as pH or calcium sensors is inherently important since ion concentrations 
are key to many relevant biochemical processes.[214] Therefore, sensors have to be placed in 
distinct distances in relation to the lipid membrane. Here, a new approach was presented, 
utilizing rigid 14-helices and MIET measurements to determine distances in dependency on 
the peptide lengths. As a proof of concept, two peptides with different lengths were synthe-
sized (Figure 44).  
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Figure 43: Schematic overview of ion translocation induced by transmembrane β-peptides and results from 
various assays. Proton influx and efflux was shown to be induced by the standard transmembrane domain 
model system upon incorporation into lipid membranes. Furthermore, conductivity measurements of lipid bi-
layers revealed that proton translocation as well as potassium ion translocation can take place with these pep-
tides. In the case of high-salt buffers and higher concentrations of peptide, even single opening events can be 
monitored. 
 
One was designed in a way that the height of the fluorophore accords to bilayer thickness 
upon peptide incorporation. The other peptide was synthesized with two additional turns. 
Considering a transmembrane peptide tilt of 16°, fluorophore heights of both peptides were 
calculated with 4.42 nm and 5.36 nm, respectively. In MIET measurements, point-to-point 
distances of fluorescent probes can be determined in relation to a sheet of graphene. Per-
formed by A. SHARMA, experimental end-to-end distances of 5.5 ± 0.4 nm and 6.2 ± 0.2 nm 
were calculated (Figure 45). However, slightly higher values were expected due to the size 
of the used Atto643 dye.  
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Figure 45: Schematic view on the developed molecular ruler based on transmembrane 14-helices. 
 
Also, the distinct height distribution of elongated transmembrane 14-helices gives evidence 
that this peptide is successfully incorporated into lipid bilayers and remain their helical struc-
ture after penetration of the lipid-water interface. With this established proof of principle, 
one can modify the synthesized peptides with analytical probes in order to investigate the 
near-membrane environment as a function of the distance to the membrane. For example, 
sensors for protons, calcium or other ions can be attached to the 14-helices, determining 










6 Experimental Part 
 
In the following chapter, all experimental details and procedures are listed which were ap-
plied in order to obtain all compounds and self-performed measurement data of this work. 
For general techniques, which were used in the laboratory, see section 6.1. Spectroscopic 
and spectrometric details and devices can be found in section 6.2, whereas all procedures, 
either for application of the compounds or syntheses can be found in sections 6.3 and 6.4 





All reagents were used as supplied. Amino acids and their respective derivatives were pur-
chased from BLD PHARMATECH LTD. (Shanghai, China), IRIS BIOTECH (Marktredwitz, Ger-
many) and CARBOLUTION CHEMICALS GMBH (St. Ingbert, Germany). Resins and coupling 
reagents were obtained from NOVABIOCHEM (Darmstadt, Germany), GL BIOCHEM (Shang-
hai, China), FLUOROCHEM LTD (Hadfield, UK), CARL ROTH GMBH (Karlsruhe, Germany), 
BACHEM (Bubendorf, Switzerland) and CARBOLUTION CHEMICALS GMBH (St. Ingbert, Ger-
many). Lipids were provided by AVANTI POLAR LIPIDS (Alabama, USA). Other chemicals 
and solvents were purchased from FLUKA (Taufkirchen, Germany), FISHER SCIENTIFIC U.K. 
LTD (Loughborough, UK), FLUOROCHEM LTD (Hadfield, UK), TCI (Tokio, Japan), 
GRÜSSING GMBH (Filsum, Germany), VWR INTERNATIONAL (Fontenay-sous-Bois, France), 
ALFA AESAR (Karlsruhe, Germany) and SIGMA-ALDRICH (Taufkirchen, Germany). Dry sol-
vents were obtained from ACROS ORGANICS (Geel, Belgium) and stored over molecular 
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sieves (4 Å). Technical grade solvents were purified prior to use. Atto fluorophores were 
provided by ATTO-TEC GMBH (Siegen, Germany) and ultra-pure water was obtained by 
using the water purification system arium® mini from SARTORIUS AG (Göttingen, Germany). 
 
Reactions 
Air and water sensitive reactions were accomplished by using the SCHLENK-technique. 
Thereby, the respective glass apparatus was heated to over 100 °C under reduced pressure. 
After cooling down and flushing the apparatus with argon gas (> 99.999 %), this process 
was repeated twice to obtain an air- and water-free atmosphere. 
 
Lyophilization 
For storage, building blocks and peptides were freeze-dried from aqueous solutions or diox-
ane containing aqueous solutions with a CHRIST Alpha-2-4-lyophilizer device (Osterode am 
Harz, Germany) which was connected to a high vacuum pump. For low amounts of solvents, 
the samples were transferred to EPPENDORF safe-lock tubes (Hamburg, Germany) and 




Chemicals and solvents were stored according to the supplier’s recommendations. Stock so-
lutions of acids, bases and salts were stored at rt, whereas aqueous buffers were stored at 
+4 °C. Modified resins were washed with DCM (3 × 5 mL) and Et2O (3 × 5 mL) prior to 
drying and storing them at rt under reduced pressure. Synthesized and cleaved peptides were 
lyophilized and kept at -20 °C or under vacuum over P2O5 or CaCl2 at rt. 
 
Thin layer chromatography (TLC) 
In order to monitor completion of reactions, TLC was performed using thin layer plates of 
silica gel (silica gel 60, F254, layer thickness 0.25 mm) on aluminum foil from MERCK KGAA 
(Darmstadt, Germany). Fluorescent samples were monitored at 254 nm or were stained with 
3 % ninhydrin solution in ethanol followed by vigorous heating to detect amines. 
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Flash column chromatography 
Building blocks were purified by carrying out flash column chromatography with an over-
pressure of 0.5 – 0.8 bar. A glass column was packed with wet silica gel (silica gel 60, F254, 
40-63 µm) and the sample was applied as a concentrated solution or adsorbed onto silica gel 
prior to use.  
 
High performance liquid chromatography (HPLC) 
Purification of peptides was carried out by using RP-HPLC with a MD-2010 Plus detector, 
PU-2080 Plus pumps, an LC-NetII/ADC interface and a DG-2080-53 degasser from Jasco 
(Tokyo, Japan). The software ChromNav 2.01.06 was used to analyze obtained chromato-
grams. Ultraviolet (UV)-absorption was detected at 215 nm, 254 nm and 280 nm for non-
labeled peptides. In presence of fluorophores, detection at 254 nm was replaced by the re-
spective fluorophore absorption wavelength (464 nm for NBD, 565 nm for TAMRA, 
643 nm for Atto643).  
For purification, a linear gradient from A (water + 0.1 % TFA + 0.1 % HFIP) to B (MeOH 
+ 0.1 % TFA + 0.1 % HFIP) and subsequent washing with 100 % B for 10 min while using 




Nuclear magnetic resonance spectroscopy 
NMR spectroscopy was performed with a BRUKER (Billerica, USA) spectrometer (av300 or 
av301), respective spectra being recorded at ambient temperature. Chemical shifts (δ) are 
given in ppm in relation to TMS, whereas the used deuterated solvents are listed below the 
respective compounds. Coupling constants are given as nJx,y in Hz with n describing the 
order of coupling and x,y denoting the coupling atoms. The following abbreviations are used 
for the listed multiplets: br (broad), s (singlet), d (doublet), t (triplet), q (quartet) or m (mul-
tiplet). 
 




Mass spectra were obtained by using a BRUKER maXis or micrOTOF device (Billerica, USA) 
using the electrospray-ionization (ESI) technique. Respective samples were dissolved in 
MeOH and acidified with formic acid prior to the measurements. Mass-to-charge ratios as 
well as high resolution peaks are listed below the respective compounds. 
 
UV/Vis spectroscopy 
Peptide concentrations were determined in MeOH solutions by performing UV spectroscopy 
with a THERMO SCIENTIFIC Nanodrop ND-200c spectrophotometer (Waltham, USA) using 
a Suprasil® quartz glass precision cell (type: 115B-QS, light path: 10.00 mm) from HELLMA 
(Müllheim, Germany) at ambient temperature. According to Lambert-Beer’s law (equation 
6.1), intensities were used to calculate the peptide concentration in solution. Thereby, the 
concenctration c was determined by dividing the absorbance A by the extinction coefficient 
ε and the light path d. Respective extinction coefficients at their specific wavelength are 







Table 3: Extinction coefficients for the determination of peptide concentrations according to Lambert-Beer's 
law. [215,216] 
 Absorption wavelength / nm Extinction coefficient / cm∙M-1 
Tryptophan 280 5690 
NBD 466 22000 
TAMRA 565 91000 
 
 
Circular dichroism spectroscopy  
To ensure successful 14-helix formation of the synthesized peptides, CD spectroscopic 
measurements in MeOH were performed. The spectra were obtained by using a JASCO J-
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1500 device (Tokyo, Japan) with a Suprasil® quartz glass precision cell (type: 110-QS, light 
path: 0.5 mm or 1.0 mm) from HELLMA (Müllheim, Germany) at 25 °C. The sample holder 
was flushed continuously with nitrogen, measurement parameters were as the following: 
measure range: 250-190 nm, data pitch: 1.0 nm, CD scale: 2000 mdeg/1.0 dOD, D.I.T.: 1 s, 
bandwith: 1.0 nm, start mode: immediately, scanning speed: 20 nm/min, accumulations: 10. 
All measurements were background-corrected by subtracting the spectrum of the pure sol-
vent. Finally, all resulting spectra were normalized according to GREENFIELD.[128]  
 
Dynamic light scattering 
Determination of size distribution of extruded vesicles was achieved by using a Zetasizer 
Nano S light scattering system from MALVERN INSTRUMENTS (Malvern, UK) with disposa-
ble PS cuvettes from BRAND (Wertheim, Germany). After application of a laser beam 
(633 nm, 4 mW), light scattering was measured at an angle of 173° at 25 °C. All other meas-
urement parameters were automatically set by the device. 
 
Fluorescence spectroscopy 
Fluorescence spectroscopic measurements were carried out on a JASCO FP-8200 device 
(Tokyo, Japan), equipped with an ETC-272T thermostat while using Suprasil® quartz glass 
precision cells (type: 119.004-QS or 111-QS, light path: 10.00 mm) from HELLMA (Müll-
heim, Germany). For proton assays, time course fluorescence emission was measured at 
512 nm with an excitation wavelength of 458 nm at 20 °C. The vesicle solution was trans-
ferred to the cuvette and diluted with buffer at pH 6.4 or 8.4 (5 mM HEPES, 100 mM KCl) 
to a volume of 792 µL. After obtaining a steady baseline, 8 µL of peptide solution in iPrOH 
or DMSO in different concentrations was added, resulting in different peptide to lipid ratios 
with a final lipid concentration of 50 µM. After the measurements, 16 µL of Triton™ X-100 
(aq., 10 %) were added to lyze the liposomes. In terms of analysis, the fluorescence intensi-
ties were normalized to the resulting baseline or the initial one depending on whether proton 
efflux or influx was determined.  
For FRET measurements, DOPC lipids (2 mg/mL) with a P/L ratio of 1:500 were used. The 
mole fraction of NBD-labeled peptides was kept at 0.5 through all measurements with var-
ying amounts of labeled TAMRA peptide from 0-0.5. In order to keep the total peptide con-
centration constant, acetylated peptides were added when necessary. After excitation at 
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464 nm, emission spectra were recorded in a range from 500 – 650 nm at 25 °C as well as at 
60 °C. Excitation and emission bandwidth of 5.0 nm, data pitch of 1.0 nm, ‘fast’ response 
mode and ‘high’ or ‘medium’ sensitivity mode lead to the obtained spectra. All spectra were 
background corrected and referenced by subtracting the emission of vesicle solution with no 
peptide content. 
 
6.3 Standard Operating Procedures (SOPs) 
 
6.3.1 Synthesis of β3-D-Amino Acids 
 
SOP1: Titration of ethereal diazomethane solutions[217,218] 
Diazomethane for β3-D-amino acid syntheses was kindly provided by D. FRANK in diethyl 
ether solutions. In order to determine the concentration of diazomethane, a titration accord-
ing to ARNDT was performed. Thereby, benzoic acid (1.30 g) was dissolved in diethyl ether 
(50 mL) and cooled to 0 °C. Diazomethane (3.00 mL) was added at 0 °C and the mixture 
was titrated with phenolphthalein against KOH (85 %, 1.30 g in 100 mL water) until a color 
change appeared (colorless to pink). According to equation 6.2, the concentration of diazo-
methane was determined with VKOH being the used amount of KOH solution until color 
change appears. 
 
 𝑐diazomethane = (𝑛benzoic⁡acid − 𝑐KOH ∙ 𝑉KOH) ∙ 𝑉diazomethane
−1  (6.2) 
 
SOP2: Synthesis of N-protected D-amino acid diazo ketones[219,220] 
 
Adapting the procedure of GUICHARD et al., under an argon atmosphere, the respective N-
terminally protected α-D-amino acid (1.00 eq) was dissolved in dry THF (4.7 mL/mmol) and 
cooled to 0 °C. After addition of triethylamine (1.10 eq) and isobutyl chloroformate 
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(1.10 eq) at 0 °C, the reaction mixture was stirred vigorously for 30 min at 0 °C. Diazome-
thane in diethyl ether (2.00 eq, see SOP1) was added under the exclusion of light, followed 
by stirring at rt until complete conversion was monitored via TLC (usually 4 – 5 hours). The 
reaction was quenched with glacial acetic acid (0.11 mL/mmol) and taken up in 6 % 
NaHCO3 solution (aq., 8.1 mL/mmol). After extraction with ethyl acetate (3 × 100 mL), the 
organic phases were dried over MgSO4 and the solvent was removed under reduced pressure 
to obtain the D-amino acid diazo ketones as a yellow solid or oil in quantitative yield. 
 
SOP3: Synthesis of N-protected β3-D-amino acid derivatives via sonication[219,220] 
 
Based on procedures of GUICHARD et al., respective D-amino acid diazo ketones (1.00 eq) 
were dissolved in a mixture of THF and water (9:1, v/v, 6.1 mL/mmol) and silver benzoate 
(0.10 eq) was added under the exclusion of light. The mixture was sonicated until completion 
was observed via TLC (usually 2 h). Water (50 mL) was added, the pH was adjusted to 2-3 
with 1 M HCl solution (aq.) and the mixture was extracted with ethyl acetate (3 × 100 mL). 
After drying over MgSO4 and concentrating the organic phases under reduced pressure, the 
raw product was added dropwise to cold pentane (-22 °C) to obtain the respective β3-D-
amino acid as a light yellow or colorless solid. 
 
SOP4: Synthesis of N-protected β3-D-amino acid derivatives via microwave irradiation[221] 
 
According to PATIL et al., respective D-amino acid diazo ketones (1.00 eq) were dissolved 
in a mixture of 1,4-dioxane and water (2:1, v/v, 12.1 mL/mmol) and silver benzoate (0.10 eq) 
was added under the exclusion of light. The reaction mixture was irradiated in a domestic 
microwave oven at 460 W for 1 min. The organic solvent was removed under reduced pres-
sure and the residual solution was diluted with water (50 mL). After adjusting the pH to 2-3 
with 1 M HCl solution (aq.), the mixture was extracted with ethyl acetate (3 × 100 mL) and 
the organic phases were concentrated under reduced pressure. Dropwise addition to cold 
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pentane (-22 °C) resulted in the respective β3-D-amino acid derivatives as a light yellow or 
colorless solid. 
 
6.3.2 Synthesis of β3-Peptides 
 
SOP5: Manual solid-phase peptide synthesis[74,220] 
Manual SPPS was performed in a BECTON-DICKINSON Discardit II syringe (Heidelberg, Ger-
many) equipped with a PE-filter. The NOVABIOCHEM® NovaPEG rink amide resin LL 
(Darmstadt, Germany) with an initial occupancy between 170 and 200 µmol/g was swollen 
in DMF for 2 h prior to use. Coupling syntheses were performed in a Discover microwave 
device from CEM (Kamp-Lintfort, Germany). The following set of steps was repeated for 
all respective β3-D-amino acids (also see SOP6) until the desired peptide sequence was 
achieved: 
1. Fmoc-deprotection was obtained by two microwave assisted steps (50 W, 65 °C, 30 s 
and 25 W, 65 °C, 3 min). Thereby, deprotection solution consisting of NMP, piperi-
dine and DBU (79:20:1, v/v/v) was added until the resin was covered. After success-
ful deprotection, the resin was washed with MeOH (3 × 5 mL) and DMF (3 × 5 mL). 
2. Desired β3-D-amino acids (5.00 eq) were activated with 500 mM HOAt (5.00 eq), 
500 mM HATU (5.00 eq) and 2.00 M DIPEA (10.0 eq) in NMP. After addition to the 
resin and double coupling (25 W, 65 °C, 15 min), the resin was washed with MeOH 
(3 × 5 mL) and DMF (3 × 5 mL). 
3. Free remaining amino groups were capped (25 W, 65 °C, 3 min) with a solution con-
sisting of acetic anhydride and NMP (1:4, v/v). Afterwards, the resin was washed 
with MeOH (3 × 5 mL) and DMF (3 × 5 mL). 
Once the desired sequence was achieved, the resin was washed with MeOH (3 × 5 mL), 
DMF (3 × 5 mL), MeOH (3 × 5 mL), DCM (3 × 5 mL) and Et2O (3 × 5 mL) before drying 
under reduced pressure at rt. 
 
SOP6: Occupancy determination of rink amide resins[222] 
After coupling of the first amino acid, the occupancy of the resin was determined according 
to a procedure of GUDE et al. 5.0 mg of resin (mresin) were added to a graduated flask (10 mL), 
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followed by addition of 2 % DBU solution in DMF (2.00 mL). The mixture was shaken for 
1 h at rt and then diluted with MeCN to achieve a final volume of 10 mL. After further 
dilution (dilution factor f: 12.5) with MeCN, the mixture was transferred to a quartz glass 
precision cell with a specific volume V. At 304 nm, the formed Fmoc-dibenzofulven moiety 
was UV spectroscopically examined as well as a blank solution without resin. The blank 
spectrum was subtracted to obtain the absorbance abs304 and the occupancy ρ was deter-
mined in mmol/g according to equation 6.3 using the extinction coefficient ε and the light 
path d. 
 
 𝜌 = 𝑚resin
−1 ∙




SOP7: Automated SPPS[74] 
β3-D-Peptides were also synthesized on a Liberty Blue™ synthesizer equipped with a Dis-
cover microwave device from CEM (Kamp-Lintfort, Germany). For a 0.04 mmol scale, the 
swollen resin was filled into the reaction vessel, amino acid concentrations were set to 0.2 M 
in DMF. Deprotection was carried out twice by using a solution of DMF, piperidine and 
DBU (79:20:1, v/v/v). For every amino acid, double coupling was performed. The first cou-
pling step was achieved by activation with 500 mM DIC (10.0 eq), 1.00 M Oxyma (5.00 eq) 
and 100 mM DIPEA (0.50 eq) in DMF, whereas the second one was performed comparable 
to the manual SPPS with 500 mM HATU (5.00 eq), 500 mM HOAt (5.00 eq) and 2.00 M 
DIPEA (10.0 eq). Capping was carried out with a solution of acetic anhydride and DMF 
(1:4, v/v). After completion of the peptide synthesis, the resin was transferred into a BECTON-
DICKINSON Discardit II syringe (Heidelberg, Germany) equipped with a PE-filter. Finally, 
the resin was washed with MeOH (3 × 5 mL), DMF (3 × 5 mL), MeOH (3 × 5 mL), DCM 
(3 × 5 mL) and Et2O (3 × 5 mL) before drying under reduced pressure at rt. Respective mi-
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Table 4: Applied microwave methods for automated SPPS. 
 Microwave methods 
Deprotection 1. 140 W, 70 °C, 180 s 
First coupling 
1. 0 W, 25 °C, 60 s 
2. 190 W, 75 °C, 15 s 
3. 35 W, 90 °C, 285 s 
4. 0 W, 25 °C, 60 s 
Second coupling 
1. 0 W, 25 °C, 60 s 
2. 43 W, 75 °C, 1140 s 
Capping 
1. 65 W, 65 °C, 30 s 
2. 0 W, 65 °C, 30 s 
3. 65 W, 65 °C, 30 s 
4. 0 W, 65 °C, 30 s 
 
 
SOP8: 4-Methyltrityl (Mtt) deprotection[223] 
According to the NOVABIOCHEM® Peptide Synthesis catalog, Mtt protecting groups were 
cleaved by adding a mixture of TFA, DCM and MeOH (1:98:1, v/v/v, 15 mg/mL). The resin 
was drained after 1 min and fresh deprotection solution was added, leaving the resin to agi-
tate for 16 h at rt. Completion of the reaction was monitored by performing the trityl test. 
Therefore, a small sample of the resin was washed with DCM and TFA was added to this 
sample. Remaining trityl groups lead to an instant color change to yellow or orange. If this 
was the case, the resin was shaken for another 1 h at rt. Once the trityl test was negative, the 
resin was drained completely and washed with DMF (3 × 5 mL), 10 % DIPEA in DMF 
(3 × 5 mL) and DMF (3 × 5 mL) again. 
 
 
SOP9: p-Nitrobenzyloxycarbonyl (pNZ) deprotection[124] 
Adapting the procedure of ISIDRO-LLOBET et al., pNZ deprotection was achieved by addition 
of a mixture of 6 M SnCl2 and 1.6 mM HCl/dioxane in DMF to the resin until it was covered 
completely. After shaking for 30 min at rt, the process was repeated once and the resin was 
drained. Thorough washing with DMF, DMF/H2O (1:1, v/v), THF/H2O (1:1, v/v), DMF, 
DCM, MeOH and DMF (3 × 5 mL each) lead to the pNZ-deprotected resin. 
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SOP10: Cleavage 
β3-Peptides were cleaved from the dry rink amide resin by adding a mixture TFA/TIS/H2O 
(95:2.5:2.5, v/v/v) and shaking for 2 h at rt. The drained solution was then concentrated under 
a nitrogen stream and cold ether (-20 °C) was added. The resulting precipitate was centri-
fuged (9000 rpm, 15 min, -5 °C) and washed with cold ether. After decantation, the crude 
peptide was dried under reduced pressure at rt. It has to be noted that all acid-labile protecting 
groups (Boc and Mtt) are deprotected during the course of a cleavage for final peptides as 
well as intermediate products and are therefore not detectable in mass spectrometry. 
 
6.3.3 Preparation of Large Unilamellar Vesicles (LUVs) 
 
SOP11: Vesicle preparation via extrusion[224,225] 
For establishing LUVs via the extrusion method, lipid films of defined lipid compositions 
were prepared in small test tubes. Therefore, lipids were dissolved in chloroform (2 mg/mL 
or 10 mg/mL) at 0 °C and if desired, peptide solutions in methanol were added to obtain a 
certain P/L ratio. Afterwards, the mixture shaken at 300 rpm at 50 °C under a nitrogen 
stream, resulting in a thin lipid film on the wall of the test tube. Complete drying was 
achieved with a vacuum oven which was used overnight at 50 °C. To obtain a vesicle solu-
tion, the lipid film was then rehydrated with buffer (500 or 1000 µL) and gently shaken for 
at least 1 h at 40 °C. Prior to extrusion, 5 cycles of vortexing for 1 min and shaking for 4 min 
at 40 °C were performed. Finally, the lipid suspension was extruded 31 times with a Lipo-
soFast-Basic extruder from AVESTIN (Ottawa, Canada) and transferred to a glass vial. For 
defined vesicle sizes, polycarbonate membranes with a specific pore size as well as What-
man polyester drain discs from GE HEALTHCARE (Little Chalfont, UK) were used. 
 
SOP12: Size exclusion chromatography of LUVs 
Prepared LUVs were purified by using a the respective buffer and Sephadex® G-50 gel fil-
tration medium from SIGMA-ALDRICH (Taufkirchen, Germany). A small glass column was 
packed with the wet dextran gel and size exclusion chromatography was performed at at-
mospheric pressure with the sample being added in buffer solution onto the column.  
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SOP13: Phosphate test[226] 
Lipid concentrations of extruded LUVs were determined by analyzing the amount of phos-
phorus in the lipid solution. Therefore, a stock solution of NaH2PO4∙H2O (89.0 mg/L) was 
used to create calibration samples with phosphorus contents ranging from 0 to 2 µg, diluting 
every sample with ultra-pure water to a total volume of 100 µL. Then, 22.0 µL of the respec-
tive vesicle solution was treated with 200 µL of 70 % perchloric acid (aq.). After heating all 
samples to 220 °C for 1 h, they were cooled down to rt again and treated with 700 µL of an 
aqueous solution consisting of 0.45 % NH4MoO4 and 12.6 % HClO4 as well as 700 µL of 
an aqueous solution of 1.70 % ascorbic acid. After vortexing every sample, they were incu-
bated for 7.5 min at 80 °C in a water bath. The resulting molybdenum complex was then 
analyzed via UV/Vis spectroscopy, measuring the absorbance at 820 nm. Using the calibra-
tion samples, a linear fit was calculated to derive the phosphorus content depending on the 
measured intensity. 
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6.4 Synthetic Procedures 
 
6.4.1 Synthesis of Cyanuric Acid and Melamine modified β3-Amino Acids 
 







Conversion of Boc-D-Lys(Cbz)-OH (7.60 g, 20.0 mmol, 1.00 eq) was achieved by following 
SOP2 and SOP3, resulting in product 9 (7.39 g, 18.7 mmol, 93 %) as a colorless solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.2 (sbr, 1 H, COOH), 7.40-7.28 (m, 5 H, 5 × 
Cbz-CHar), 7.24-7.15 (m, 1 H, Cbz-NH), 6.66 (d, 1 H, 
3JH,H = 8.7 Hz, Boc-NH), 4.99 (s, 2 H, 
Cbz-CH2), 3.79-3.63 (m, 1 H, β-CH), 3.00-2.86 (m, 2 H, ζ-CH2), 2.39-2.17 (m, 2 H, α-CH2), 
1.42-1.16 (m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 393.2 [M-H]-, 395.2 [M+H]+, 417.4 [M+Na]+, 811.7 [2M+Na]+.  
HR-MS (ESI): calc. for [C20H29N2O6]
- ([M-H]-): 393.2031, found: 393.2027, calc. for 
[C20H31N2O6]
+ ([M+H]+): 395.2177, found: 395.2193, calc. for [C20H30N2O6Na]
+ 
([M+Na]+): 417.1996, found: 417.1978. 
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Boc-β3-D-Lys(Cbz)-OH (13.5 g, 34.2 mmol, 1.00 eq) was dissolved in degassed ethanol 
(230 mL) and Pd/C (5 %, 3.64 g) was added to the solution. The mixture was stirred over-
night with an overpressure of 4.5 bar of hydrogen gas at rt. Then, it was filtered through 
Celite®, followed by removal of the organic solvent under reduced pressure. Compound 11 
(8.32 g, 32.0 mmol, 94 %) was obtained as a colorless solid. 
1H-NMR (300 MHz, methanol-d4): δ/ppm = 3.90-3.76 (m, 1 H, β-CH2), 2.97-2.86 (m, 2 H, 
ζ-CH2), 2.41-2.21 (m, 2 H, α-CH2), 1.74-1.36 (m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 261.2 [M+H]+, 283.2 [M+Na]+.  
HR-MS (ESI): calc. for [C12H25N2O4]
+ ([M+H]+): 261.1809, found: 261.1812, calc. for 
[C12H24N2O4Na]
+ ([M+Na]+): 283.1628, found: 283.1632. 
  










Boc-β3-D-Lys-OH (4.99 g, 19.2 mmol, 1.00 eq) was dissolved in H2O (54 mL) and added to 
a suspension of 2,4-diamino-6-chlorotriazine (3.35 g, 23.0 mmol, 1.20 eq) in H2O (13 mL). 
NaOH (1.53 g, 38.3 mmol, 2.00 eq) in H2O (38 mL) was added dropwise and the mixture 
was stirred overnight at 85 °C. After cooling to rt, the solution was filtered and adjusted to 
pH 5 with 1 M HCl (aq.) at 0 °C. The resulting precipitate was filtered, washed with H2O 
(2 × 15 mL) and dried under reduced pressure to obtain compound 12 as a colorless solid 
(2.49 g, 6.74 mmol, 35 %). 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 6.66 (d, 1 H, 
3JH,H = 8.7 Hz, Boc-NH), 6.42 (t, 
1 H, 3JH,H = 5.8 Hz, melamine-NH), 6.18-5.83 (m, 4 H, 2 × NH2), 3.77-3.63 (m, 1 H, β-CH), 
3.15-3.06 (m, 2 H, ζ-CH2), 2.37-2.20 (m, 2 H, α-CH2), 1.41-1.29 (m, 15 H, 3 × CH3, γ-CH2, 
δ-CH2, ε-CH2).  
ESI-MS (m/z): 370.2 [M+H]+, 392.2 [M+Na]+.  
HR-MS (ESI): calc. for [C15H28N7O4]
+ ([M+H]+): 370.2197, found: 370.2207, calc. for 
[C15H27N7O4Na]
+ ([M+Na]+): 392.2017, found: 392.2027. 
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(R)-7-(4,6-Diamino-1,3,5-triazine-2-yl)-amino-3-(9-fluorenylmehyloxycarbonyl)-amino-







Boc-β3-D-Lys(M)-OH (568 mg, 1.54 mmol, 1.00 eq) was dissolved in TFA (5 mL) and H2O 
(100 µL) and stirred for 1 h at rt. After removing TFA in a nitrogen stream, the residue was 
suspended in H2O (50 mL) and adjusted to pH 7 with saturated NaHCO3 solution (aq.). 
NaHCO3 (194 mg, 2.31 mmol, 1.50 eq) was added and Fmoc-OSu (795 mg, 2.31 mmol, 
1.50 eq) in 1,4-dioxane (11 mL) was added dropwise at 0 °C. The mixture was stirred for 
1 h at 0 °C and then at rt overnight. Afterwards, H2O (25 mL) was added and the organic 
solvent was removed under reduced pressure. The aqueous phase was extracted with ethyl 
acetate (2 × 100 mL) and then adjusted to pH 1 with 1 M HCl (aq.) at 0 °C. The resulting 
precipitate was filtered, washed with H2O (2 × 15 mL) and dried under reduced pressure to 
gain compound 13 (440 mg, 895 µmol, 58 %) as a colorless solid.  
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 7.91-7.76 (m, 2 H, 2 × Fmoc-CHar), 7.69-7.57 
(m, 2 H, 2 × Fmoc-CHar), 7.43-7.31 (m, 4 H, 4 × Fmoc-CHar), 4.34-4.13 (m, 3 H, Fmoc-CH, 
Fmoc-CH2), 3.81-3.67 (m, 1 H, β-CH), 2.38-2.27 (m, 2 H, ζ-CH2), 2.25-2.19 (m, 2 H, α-
CH2), 1.50-1.12 (m, 6 H, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 492.2 [M+H]+, 983.5 [2M+H]+, 490.2 [M-H]-.  
HR-MS (ESI): calc. for [C25H30N7O4]
+ ([M+H]+): 492.2354, found: 492.2357, calc. for 
[C25H28N7O4]
- ([M-H]-): 490.2208, found: 490.2195. 
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Boc-β3-D-Lys-OH (5.00 g, 19.2 mmol, 1.00 eq) was dissolved in H2O (74 mL) and 4 M 
NaOH (aq., 7.4 mL) was added at 60 °C. Sodium nitroprusside (8.74 g, 29.3 mmol, 1.53 eq) 
and 4 M NaOH (aq., 7.4 mL) were added in small portions over 1 h and the mixture was 
stirred for 5 h at 60 °C. After cooling to 10 °C and adjusting the pH to 2-3 with 1 M HCl 
(aq.), the aqueous solution was extracted with ethyl acetate (3 × 100 mL), dried over MgSO4 
and the solvent was removed under reduced pressure. Flash column chromatography of the 
residue (DCM/MeOH = 24:1 + 0.25 % AcOH → 9:1 + 1.00 % AcOH) lead to compound 14 
(2.51 g, 9.61 mmol, 50 %) as a yellow oil. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 6.64 (d, 1 H, 
3JH,H = 8.9 Hz, Boc-NH), 3.81-3.63 
(m, 1 H, β-CH), 3.35 (t, 2 H, 3JH,H = 6.3 Hz, ζ-CH2), 2.32-2.24 (m, 2 H, α-CH2), 1.47-1.22 
(m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 262.2 [M+H]+, 284.2 [M+Na]+, 545.3 [2M+Na]+.  
HR-MS (ESI): calc. for [C12H24NO5]
+ ([M+H]+): 262.1649, found: 262.1657, calc. for 
[C12H23NO5Na]
+ ([M+Na]+): 284.1468, found: 284.1480. 
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Under an argon atmosphere, Boc-β3-D-Lys(OH)-OH (232 mg, 888 µmol, 1.00 eq) was dis-
solved in THF (10 mL) and CBr4 (422 mg, 1.27 mmol, 1.45 eq) was added at 0 °C. After 
stirring for 30 min at 0 °C, a PPh3-Polymer (1.90 g, 1.0-1.5 mmol/g, 2.10 eq) was added and 
the mixture was stirred for 1 h at 0 °C and then overnight at rt. The suspension was filtered 
through Celite®, washed with THF (3 × 5 mL) and the solvent was removed under reduced 
pressure. Flash column chromatography (DCM/MeOH = 24:1 + 0.40 % AcOH) lead to com-
pound 15 (171 mg, 529 µmol, 60 %) as a colorless solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.1 (sbr, 1 H, COOH), 6.69 (d, 1 H, 
3JH,H = 
9.0 Hz, Boc-NH), 3.83-3.65 (m, 1 H, β-CH), 3.50 (t, 2 H, 3JH,H = 6.6 Hz, ζ-CH2), 2.38-2.21 
(m, 2 H, α-CH2), 1.38-1.35 (m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 346.1 [M(79Br)+Na]+, 348.1 [M(81Br)+Na]+.  
HR-MS (ESI): calc. for [C12H22
79BrNO4Na]
+ ([M+Na]+): 346.0624, found: 346.0625, calc. 
for [C12H22
81BrNO4Na]
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Under an argon atmosphere, Boc-β3-D-Lys(Br)-OH (1.01 g, 3.12 mmol, 1.00 eq) and cy-
anuric acid (2.01 g, 15.6 mmol, 5.00 eq) were dissolved in dry DMF (20 mL) and DBU 
(470 µL, 3.12 mmol, 1.00 eq) was added dropwise at rt. The mixture was stirred for 2 d at 
70 °C and the solvent was then removed under reduced pressure. The residue was suspended 
in H2O (50 mL) and the pH was adjusted to 5 with 1 M HCl (aq.). DCM (50 mL) was added 
and excessive cyanuric acid was separated via filtration. The mixture was extracted with 
DCM (3 × 50 mL), dried over MgSO4 and purified by performing flash column chromatog-
raphy (DCM/MeOH = 24:1 + 0.50 % AcOH → 9:1 + 0.50 % AcOH). Product 16 (275 mg, 
738 µmol, 24 %) was obtained as a colorless solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 6.81-6.59 (m, 1 H, Boc-NH), 3.80-3.50 (m, 3 H, 
β-CH, ζ-CH2), 2.27-2.01 (m, 2 H, α-CH2), 1.51-1.11 (m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-
CH2). 
ESI-MS (m/z): 373.2 [M+H]+, 395.2 [M+Na]+.  
HR-MS (ESI): calc. for [C15H25N4O7]
+ ([M+H]+): 373.1718, found: 373.1701, calc. for 
[C15H24N4O7Na]













Boc-β3-D-Lys(CA)-OH (267 mg, 717 µmol, 1.00 eq) was dissolved in a mixture of TFA and 
H2O (95:5, v/v, 10.5 mL) and stirred for 1 h at 0 °C, followed by stirring for 1 h at rt. Exces-
sive TFA was removed in a nitrogen stream and coevaporated with toluene (3 × 25 mL). 
After lyophilization, the residue was dissolved in H2O (5 mL), neutralized with saturated 
NaHCO3 solution (aq.) and NaHCO3 (91.0 mg, 1.08 mmol, 1.51 eq) was added. Fmoc-OSu 
(363 mg, 1.08 mmol, 1.51 eq) in 1,4-dioxane (5 mL) was added dropwise at 0 °C and the 
mixture was stirred for 1 h at 0 °C, followed by stirring overnight at rt. The solvent was 
removed under reduced pressure and the remaining product was purified via flash column 
chromatography (DCM/MeOH = 24:1 + 0.25 % AcOH → 9:1 + 1.00 % AcOH) to obtain 
product 17 (274 mg, 554 µmol, 77 %) as a colorless solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 7.88 (d, 2 H, 
3JH,H = 7.4 Hz, 2 × Fmoc-CHar), 
7.68 (d, 2 H, 3JH,H = 7.4 Hz, 2 × Fmoc-CHar), 7.44-7.28 (m, 4 H, 4 × Fmoc-CHar), 7.23 (d, 
1 H, 3JH,H = 8.5 Hz, Fmoc-NH), 4.35-4.16 (m, 3 H, Fmoc-CH, Fmoc-CH2), 3.77-3.68 (m, 
1 H, β-CH), 3.63-3.57 (m, 2 H, ζ-CH2), 2.35-2.15 (m, 2 H, α-CH2), 1.56-1.13 (m, 6 H, γ-
CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 495.3 [M+H]+, 517.3 [M+Na]+.  
HR-MS (ESI): calc. for [C25H27N4O7]
+ ([M+H]+): 495.1874, found: 495.1877, calc. for 
[C25H26N4O7Na]
+ ([M+Na]+): 517.1694, found: 517.1691. 
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6.4.2 Synthesis of other β3-Amino Acids 
 







Starting from Fmoc-D-Val-OH (10.0 g, 29.5 mmol, 1.00 eq), compound 3 (7.98 g, 
22.6 mmol, 77 %) was obtained by following SOP2 and SOP4 as a colorless solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.1 (sbr, 1 H, OH), 7.89 (d, 2 H, 
3JH,H = 7.4 Hz, 
2 × Fmoc-CHar), 7.74-7.66 (m, 2 H, 2 × Fmoc-CHar), 7.46-7.26 (m, 4 H, 4 × Fmoc-CHar), 
7.24 (d, 1 H, 3JH,H = 9.0 Hz, NH), 4.36-4.16 (m, 3 H, Fmoc-CH2, Fmoc-CH), 3.78-3.67 (m, 
1 H, β-CH), 2.44-2.23 (m, 2 H, α-CH2), 1.77-1.64 (m, 1 H, γ-CH), 0.88-0.77 (m, 6 H, 2 × 
CH3).  
ESI-MS (m/z): 354.2 [M+H]+, 376.3 [M+Na]+, 729.5 [2M+Na]+.  
HR-MS (ESI): calc. for [C21H24NO4]
+ ([M+H]+): 354.1700, found: 354.1699, calc. for 
[C21H23NO4Na]


















Starting from Fmoc-D-Lys(Boc)-OH (10.0 g, 21.3 mmol, 1.00 eq), compound 6 (8.15 g, 
16.9 mmol, 79 %) was obtained by following SOP2 and SOP3 as a light yellow solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.2 (sbr, 1 H, OH), 7.89 (d, 2 H, 
3JH,H = 7.7 Hz, 
2 × Fmoc-CHar), 7.68 (d, 2 H, 
3JH,H = 7.5 Hz, 2 × Fmoc-CHar), 7.46-7.28 (m, 4 H, 4 × Fmoc-
CHar), 7.21 (d, 1 H, 
3JH,H = 8.6 Hz, NH), 6.82-6.72 (m, 1 H, NH), 4.32-4.16 (m, 3 H, Fmoc-
CH2, Fmoc-CH), 3.81-3.68 (m, 1 H, β-CH), 2.92-2.83 (m, 2 H, α-CH2), 2.42-2.24 (m, 2 H, 
ζ-CH2), 1.44-1.15 (m, 15 H, 3 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 483.2 [M+H]+, 505.2 [M+Na]+, 987.5 [2M+Na]+.  
HR-MS (ESI): calc. for [C27H35N2O6]
+ ([M+H]+): 483.2490, found: 483.2494, calc. for 
[C27H38N3O6]
+ ([M+NH4]
+): 500.2755, found: 500.2752, calc. for [C27H34N2O6Na]
+ 
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Starting from Boc-D-Lys(Boc)-OH (5.00 g, 14.4 mmol, 1.00 eq), compound 8 (4.80 g, 
13.3 mmol, 92 %) was obtained by following SOP2 and SOP3 as a light yellow solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.2 (sbr, 1 H, OH), 6.76-6.68 (m, 1 H, NH), 6.63 
(d, 1 H, 3JH,H = 8.7 Hz, NH), 3.77-3.61 (m, 1 H, β-CH), 2.94-2.80 (m, 2 H, α-CH2), 2.40-
2.16 (m, 2 H, ζ-CH2), 1.37-1.26 (m, 24 H, 6 × CH3, γ-CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 361.3 [M+H]+, 378.3 [M+NH4]
+ 383.2 [M+Na]+.   
HR-MS (ESI): calc. for [C17H33N2O6]
+ ([M+H]+): 361.2333, found: 361.2339, calc. for 
[C17H36N3O6]
+ ([M+NH4]
+): 378.2599, found: 378.2597, calc. for [C17H32N2O6Na]
+ 
([M+Na]+): 383.2153, found: 383.2156. 
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(R)-4-(1'-tert-Butoxycarbonyl-indo-3'-yl)-3-(9-fluorenylmethyloxycarbonyl)-aminobuta-






Starting from Fmoc-D-Trp(Boc)-OH (5.02 g, 9.53 mmol, 1.00 eq), compound 5 (4.58 g, 
8.47 mmol, 89 %) was obtained by following SOP2 and SOP3 as a light yellow solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.3 (sbr, 1 H, OH), 8.06-7.13 (m, 14 H, 4 × 
Fmoc-CHar, Fmoc-NH, 2 × Fmoc-CHar, 2 × Fmoc-CHar, 5 × CHTrp), 4.25-4.06 (m, 3 H, 
Fmoc-CH2, Fmoc-CH), 3.69-3.61 (m, 1 H, CH), 3.39-3.25 (m, 3 H, α-CH2, γ-CH2), 2.91-
2.80 (m, 1 H, α-CH2), 1.60-1.50 (m, 9 H, 3 × CH3).  
ESI-MS (m/z): 541.2 [M+H]+, 563.2 [M+Na]+, 1103.5 [2M+Na]+.  
HR-MS (ESI): calc. for [C32H33N2O6]
+ ([M+H]+): 541.2333, found: 541.2327, calc. for 
[C32H32N2O6Na]
+ ([M+Na]+): 563.2153, found: 563.2158. 
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To a solution of 4-nitrobenzyl chloroformate (9.20 g, 42.7 mmol, 1.00 eq) in 1,4-dioxane 
(19 mL), NaN3 (3.33 g, 51.2 mmol, 1.20 eq) in H2O (13 mL) was added. The emulsion was 
stirred at rt until completion was detected via TLC (2 h). The resulting pNZ-azide was then 
treated with a solution of H-D-Val-OH (5.00 g, 42.7 mmol, 1.00 eq) in 2 % Na2CO3 solution 
(aq.) and 1,4-dioxane (1:1, v/v, 54 mL). The mixture was stirred for 24 h at rt, keeping the 
pH at 9-10 with 10 % Na2CO3 solution (aq.). After completion of the reaction, H2O (400 mL) 
was added and the solution was extracted with methyl tert-butyl ether (3 × 200 mL). The 
aqueous solution was adjusted to pH 2-3 with 3 M HCl (aq.), extracted with ethyl acetate 
(3 × 200 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude product was purified via flash column chromatography (Et2O/EtOAc = 1:1 + 1.00 % 
AcOH) and compound 28 (7.75 g, 26.2 mmol, 62 %) was obtained as a colorless solid.  
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 12.4 (sbr, 1 H, OH), 8.23 (d, 2 H, 
3JH,H = 8.7 Hz, 
2 × pNZ-CHar), 7.67-7.60 (m, 2 H, 2 × pNZ-CHar), 5.20 (s, 2 H, pNZ-CH2), 3.92 (dd, 1 H, 
3JH,H = 8.6 Hz, 5.8 Hz, α-CH), 2.17-1.99 (m, 1 H, β-CH), 0.99-0.86 (m, 6 H, 2 × CH3).  
ESI-MS (m/z): 297.1 [M+H]+, 319.1 [M+Na]+, 615.2 [2M+Na]+.  
HR-MS (ESI): calc. for [C13H17N2O6]
+ ([M+H]+): 297.1081, found: 297.1095, calc. for 
[C13H16N2O6Na]
+ ([M+Na]+): 319.0901, found: 319.0914. 
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Starting from pNZ-D-Val-OH (7.75 g, 26.2 mmol, 1.00 eq), compound 4 (5.20 g, 
16.9 mmol, 64 %) was obtained as a colorless solid by following SOP2 and SOP3 and puri-
fication via flash column chromatography (EtOAc/pentane = 1:1 + 1.00 % AcOH). 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = = 12.1 (sbr, 1 H, OH), 8.23 (d, 2 H, 
3JH,H = 8.7 Hz, 
2 × pNZ-CHar), 7.59 (d, 2 H, 
3JH,H = 8.5 Hz, 2 × pNZ-CHar), 7.34 (d, 1 H, 
3JH,H = 9.0 Hz, 
pNZ-NH), 5.16 (s, 2 H, pNZ-CH2), 3.79-3.64 (m, 1 H, β-CH), 2.45-2.21 (m, 2 H, α-CH2), 
1.77-1.63 (m, 1 H, γ-CH), 0.88-0.76 (m, 6 H, 2 × CH3).  
ESI-MS (m/z): 311.1 [M+H]+, 333.1 [M+Na]+, 643.2 [2M+Na]+.  
HR-MS (ESI): calc. for [C14H19N2O6]
+ ([M+H]+): 311.1238, found: 311.1236, calc. for 
[C14H18N2O6Na]
+ ([M+Na]+): 333.1057, found: 333.1058. 
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Starting from Fmoc-D-Lys(Mtt)-OH (10.1 g, 16.2 mmol, 1.00 eq), compound 7 (8.11 g, 
12.7 mmol, 78 %) was obtained by following SOP2 and SOP3 as a light yellow solid. 
1H-NMR (300 MHz, DMSO-d6): δ/ppm = 7.87 (d, 2 H, 
3JH,H = 7.5 Hz), 7.75-6.94 (m, 20 H, 
6 × Fmoc-CHar, 14 × Mtt-CHar), 4.28-4.19 (m, 3 × H, Fmoc-CH2, Fmoc-CH), 3.57-3.56 (m, 
1 H, β-CH), 3.22-3.14 (m, 2 H, α-CH2), 2.38.2.32 (m, 2 H, ζ-CH2), 1.53-1.30 (m, 6 H, γ-
CH2, δ-CH2, ε-CH2).  
ESI-MS (m/z): 639.4 [M+H]+, 637.4 [M-H]-.  
HR-MS (ESI): calc. for [C42H43N2O4]
+ ([M+H]+): 639.3217, found: 639.3204, calc. for 
[C42H41N2O4]
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NovaPEG rink amide resin LL (85.0 mg, 15.3 µmol, 180 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Mtt)-OH (48.9 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-
Lys(Boc)-OH (36.9 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-Trp(Boc)-OH (41.3 mg, 
76.5 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (27.0 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-
Lys(M)-OH (37.6 mg, 76.5 µmol, 5.00 eq) and Boc-β3-D-Lys(CA)-OH (28.5 mg, 
76.5 µmol, 5.00 eq). After cleavage from the resin, which was achieved by following 
SOP10, the peptide was purified via semi-preparative HPLC to obtain compound 1 as a col-
orless solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 254, 280): tR = 18.38 min. 
ESI-MS (m/z): 602.0 [M+8H]8+, 687.9 [M+7H]7+, 802.4 [M+6H]6+, 962.6 [M+5H]5+, 1203.0 
[M+4H]4+, 1603.7 [M+3H]3+.  
HR-MS (ESI): calc. for [C249H430N56O38]
8+ ([M+8H]8+): 601.6674, found: 601.6654, calc. 
for [C249H429N56O38]
7+ ([M+7H]7+): 687.4760, found: 687.4744, calc. for [C249H428N56O38]
6+ 
([M+6H]6+): 801.8875, found: 801.8863. 
 
  













NovaPEG rink amide resin LL (85.0 mg, 15.3 µmol, 180 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Mtt)-OH (48.9 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-
Lys(Boc)-OH (36.9 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-Trp(Boc)-OH (41.3 mg, 
76.5 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (27.0 mg, 76.5 µmol, 5.00 eq), Fmoc-β3-D-
Lys(M)-OH (37.6 mg, 76.5 µmol, 5.00 eq) and Boc-β3-D-Lys(CA)-OH (28.5 mg, 
76.5 µmol, 5.00 eq). After cleavage from the resin, which was achieved by following 
SOP10, the peptide was purified via semi-preparative HPLC to obtain compound 2 as a col-
orless solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 254, 280): tR = 18.45 min. 
ESI-MS (m/z): 602.0 [M+8H]8+, 687.9 [M+7H]7+, 802.4 [M+6H]6+, 962.6 [M+5H]5+, 1203.0 
[M+4H]4+.  
HR-MS (ESI): calc. for [C249H430N56O38]
8+ ([M+8H]8+): 601.6674, found: 601.6665, calc. 
for [C249H429N56O38]
7+ ([M+7H]7+): 687.4760, found: 687.4753, calc. for [C249H428N56O38]
6+ 


















NovaPEG rink amide resin LL (558 mg, 100 µmol, 180 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Mtt)-OH (321 mg, 502 µmol, 5.00 eq), Fmoc-β3-D-
Lys(Boc)-OH (242 mg, 502 µmol, 5.00 eq), Fmoc-β3-D-Trp(Boc)-OH (271 mg, 502 µmol, 
5.00 eq), Fmoc-β3-D-Val-OH (178 mg, 502 µmol, 5.00 eq) and pNZ-β3-D-Val-OH (156 mg, 
502 µmol, 5.00 eq). Compound 29 was obtained as a colorless solid and verified via mass 
spectrometry. Being an intermediate for further modifications, 29 was not purified at this 
stage. 
ESI-MS (m/z): 705.0 [M+6H]6+, 846.2 [M+5H]5+, 1057.5 [M+4H]4+, 1409.6 [M+3H]3+.  
HR-MS (ESI): calc. for [C224H377N43O35]
6+ ([M+6H]6+): 704.9835, found: 704.9803, calc. 
for [C224H376N43O35]
5+ ([M+5H]5+): 845.7787, found: 845.7791, calc. for [C224H375N43O35]
4+ 
([M+4H]4+): 1056.9716, found: 1056.9712. 
 
  














Peptide intermediate 20 was achieved by modification of 29 according to SOP8 and subse-
quent NBD-labeling. Therefore, the resin (255 mg, 45.9 µmol, 180 µmol/g, 1.00 eq) was 
treated with NBD-F (42.1 mg, 230 µmol, 5.00 eq) and DIPEA (159 µL, 115 mg, 918 µmol, 
20.0 eq) in DMF (1.0 mL) for 2 h at 65 °C under microwave irradiation (15 W). Afterwards, 
the resin was washed with DMF (15 × 5 mL) and MeOH (15 × 5 mL). pNZ deprotection 
was carried out by following SOP9, cleavage by following SOP10. Compound 20 was ob-
tained as a yellow/brown solid and verified via mass spectrometry. Being an intermediate 
for further modifications, 20 was not purified at this stage. 





5+, 1053.5 [M+4H]4+, 1064.5 
[M+4H+CO2]
4+, 1075.5 [M+4H+2CO2]
4+, 1404.3 [M+3H]3+.  
HR-MS (ESI): calc. for [C222H373N45O34]
6+ ([M+6H]6+): 702.3135, found: 702.3116, calc. 
for [C223H373N45O36]
6+ ([M+6H+CO2]
6+): 709.6451, found: 709.6433, calc. for 
[C224H373N45O38]
6+ ([M+6H+2CO2]





















NovaPEG rink amide resin LL (100 mg, 18.0 µmol, 180 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (43.4 mg, 90.0 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (48.6 mg, 90.0 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (31.8 mg, 90.0 µmol, 
5.00 eq), Fmoc-β3-D-Lys(CA)-OH (44.5 mg, 90.0 µmol, 5.00 eq), Fmoc-β3-D-Lys(M)-OH 
(44.2 mg, 90.0 µmol, 5.00 eq) and Fmoc-β3-D-Lys(Mtt)-OH (57.5 mg, 90.0 µmol, 5.00 eq). 
Compound 30 was obtained as a colorless solid and verified via mass spectrometry. Being 
an intermediate for further modifications, 30 was not purified at this stage. 
ESI-MS (m/z): 709.9 [M+7H]7+, 828.2 [M+6H]6+, 993.7 [M+5H]5+, 1241.9 [M+4H]4+.  
HR-MS (ESI): calc. for [C257H442N57O40]
7+ ([M+7H]7+): 709.6324, found: 709.6353, calc. 
for [C257H441N57O40]
6+ ([M+6H]6+): 827.7366, found: 827.7443, calc. for [C257H440N57O40]
5+ 

















NovaPEG rink amide resin LL (300 mg, 60.0 µmol, 200 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (145 mg, 300 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (162 mg, 300 µmol, 5.00 eq) and Fmoc-β3-D-Val-OH (106 mg, 300 µmol, 
5.00 eq). After cleavage from the resin, which was achieved by following SOP10, the pep-
tide was purified via semi-preparative HPLC to obtain compound 21 as a colorless solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 254, 280): tR = 30.76 min. 
ESI-MS (m/z): 708.3 [M+5H]5+, 885.1 [M+4H]4+, 1179.8 [M+3H]3+, 1769.2 [M+2H]2+.  
HR-MS (ESI): calc. for [C190H321N36O27]
5+ ([M+5H]5+): 707.8965, found: 707.8961, calc. 
for [C190H320N36O27]
4+ ([M+4H]4+): 884.6188, found: 884.6178, calc. for [C190H319N36O27]
3+ 
([M+3H]3+): 1179.1560, found: 1179.1546. 
 
  













NovaPEG rink amide resin LL (200 mg, 40.0 µmol, 200 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (96.5 mg, 200 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (108 mg, 200 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (70.7 mg, 200 µmol, 
5.00 eq) and Boc-β3-D-Lys(Fmoc)-OH (96.5 mg, 200 µmol, 5.00 eq), followed by NBD-la-
beling. Therefore, the resin was treated with NBD-Cl (24.0 mg, 120 µmol, 3.00 eq) and 
DIPEA (136 µL, 103 mg, 800 µmol, 20.0 eq) in DMF (500 µL) for 2 h at 65 °C under mi-
crowave irradiation (15 W). Afterwards, the resin was washed with DMF (15 × 5 mL) and 
MeOH (15 × 5 mL) and the peptide was cleaved according to SOP10. The crude peptide was 
purified via semi-preparative HPLC to obtain compound 23 as a yellow/brown solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 280, 464): tR = 22.06 min.  
ESI-MS (m/z): 769.3 [M+5H]5+, 961.4 [M+4H]4+, 1281.6 [M+3H]3+, 1921.9 [M+2H]2+.  
HR-MS (ESI): calc. for [C203H336N41O31]
5+ ([M+5H]5+): 768.9190, found: 768.9174, calc. 
for [C203H335N41O31]
4+ ([M+4H]4+): 960.8969, found: 960.8945, calc. for [C203H334N41O31]
3+ 


















NovaPEG rink amide resin LL (50.0 mg, 8.50 µmol, 170 µmol/g, 1.00 eq) was modified ac-
cording to SOP7 with Fmoc-β3-D-Lys(Boc)-OH (20.5 mg, 42.5 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (23.0 mg, 42.5 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (15.0 mg, 42.5 µmol, 
5.00 eq) and Boc-β3-D-Lys(Fmoc)-OH (20.5 mg, 42.5 µmol, 5.00 eq), followed by Fmoc 
deprotection and TAMRA labeling. Therefore, TAMRA (18.3 mg, 42.5 µmol, 5.00 eq), was 
activated with a mixture of 0.5 M HOAt and 0.5 M HATU in DMF (85.0 µL, 42.5 µmol, 
5.00 eq) and 2.0 M DIPEA in NMP (42.5 µL, 85.0 µmol, 10.0 eq). The activated dye was 
then added to the resin and treated with microwave irradiation (15 W) for 2 h at 65 °C. Af-
terwards, the resin was washed with DMF (15 × 5 mL) and MeOH (15 × 5 mL) and the pep-
tide was cleaved according to SOP10. The crude peptide was purified via semi-preparative 
HPLC to obtain compound 22 as a pink solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 280, 565): tR = 20.10 min.  
ESI-MS (m/z): 682.8 [M+6H]6+, 819.1 [M+5H]5+, 1023.7 [M+4H]4+, 1364.6 [M+3H]3+.  
HR-MS (ESI): calc. for [C222H356N40O32]
6+ ([M+6H]6+): 682.4571, found: 682.4577, calc. 
for [C222H355N40O32]
5+ ([M+5H]5+): 818.7471, found: 818.7469, calc. for [C222H354N40O32]
4+ 

















NovaPEG rink amide resin LL (200 mg, 40.0 µmol, 200 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (96.5 mg, 200 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (108 mg, 200 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (70.7 mg, 200 µmol, 
5.00 eq) and Boc-β3-D-Lys(Fmoc)-OH (96.5 mg, 200 µmol, 5.00 eq), followed by Fmoc 
deprotection and acetylation with a mixture of acetic anhydride and DMF (1:4, v/v, 5 mL) 
for 3 min at 65 °C under microwave irradiation (25 W). Afterwards, the resin was washed 
with DMF (3 × 5 mL) and MeOH (3 × 5 mL) and the peptide was cleaved according to 
SOP10. The crude peptide was purified via semi-preparative HPLC to obtain compound 24 
as a colorless solid.  
HPLC (semi-preparative, 80-100 % B in 30 min at 50 °C, λ/nm: 215, 254, 280): tR = 
21.10 min.  
ESI-MS (m/z): 745.1 [M+5H]5+, 931.2 [M+4H]4+, 1241.2 [M+3H]3+, 1861.3 [M+2H]2+.  
HR-MS (ESI): calc. for [C199H337N38O29]
5+ ([M+5H]5+): 744.7207, found: 744.7207, calc. 
for [C199H336N38O29]
4+ ([M+4H]4+): 930.6491, found: 930.6486, calc. for [C199H335N38O29]
3+ 
([M+3H]3+): 1240.5297, found: 1240.5293. 
  













NovaPEG rink amide resin LL (100 mg, 17.0 µmol, 170 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (41.0 mg, 85.0 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (45.9 mg, 85.0 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (30.0 mg, 85.0 µmol, 
5.00 eq) and Fmoc-β-Ala-OH (26.5 mg, 42.5 µmol, 5.00 eq), followed by Fmoc deprotec-
tion and TAMRA labeling. Therefore, TAMRA (36.6 mg, 85.0 µmol, 5.00 eq), was acti-
vated with DIC (26.3 µL, 21.4 mg, 170 µmol, 10.0 eq) and Oxyma (12.1 mg, 85.0 µmol, 
5.00 eq) in DMF (250 µL). The activated dye was then added to the resin and treated with 
microwave irradiation (15 W) for 2 h at 65 °C. Afterwards, the resin was washed with DMF 
(15 × 5 mL) and MeOH (15 × 5 mL) and the peptide was cleaved according to SOP10. The 
crude peptide was purified via semi-preparative HPLC to obtain compound 31 as a pink 
solid.  
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 280, 565): tR = 21.24 min.  
ESI-MS (m/z): 804.9 [M+5H]5+, 1005.9 [M+4H]4+, 1340.9 [M+3H]3+.  
HR-MS (ESI): calc. for [C218H346N39O32]
5+ ([M+5H]5+): 804.5324, found: 804.5323, calc. 
for [C218H345N39O32]
4+ ([M+4H]4+): 1005.4136, found: 1005.4126, calc. for 
[C218H344N39O32]



















NovaPEG rink amide resin LL (16.0 mg, 3.20 µmol, 200 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (7.70 mg, 16.0 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (8.60 mg, 16.0 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (5.70 mg, 16.0 µmol, 
5.00 eq) and Fmoc-β-Ala-OH (5.00 mg, 16.0 µmol, 5.00 eq), followed by Fmoc deprotec-
tion and Atto643 labeling. Therefore, Atto643-NHS ester (2.50 mg, 2.60 µmol, 0.81 eq) was 
dissolved in dry DMSO (400 µL) and DIPEA (2.18 µL, 1.65 mg, 12.8 µmol, 4.00 eq) was 
added. The mixture was added to the resin and treated with microwave irradiation (10 W) 
for 2 h at 37 °C, followed by shaking overnight at 37 °C. The resin was washed with DMF 
(15 × 5 mL), MeOH (15 × 5 mL) and cleaved according to SOP10. The crude peptide was 
purified via semi-preparative HPLC to obtain compound 26 as a blue solid. 
HPLC (semi-preparative, 80-100 % B in 30 min, at 40 °C, λ/nm: 215, 280, 643): tR = 
34.50 min.  


















NovaPEG rink amide resin LL (16.0 mg, 3.20 µmol, 200 µmol/g, 1.00 eq) was modified ac-
cording to SOP5 with Fmoc-β3-D-Lys(Boc)-OH (7.70 mg, 16.0 µmol, 5.00 eq), Fmoc-β3-D-
Trp(Boc)-OH (8.60 mg, 16.0 µmol, 5.00 eq), Fmoc-β3-D-Val-OH (5.70 mg, 16.0 µmol, 
5.00 eq) and Fmoc-β-Ala-OH (5.00 mg, 16.0 µmol, 5.00 eq), followed by Fmoc deprotec-
tion and Atto643 labeling. Therefore, Atto643-NHS ester (2.50 mg, 2.60 µmol, 0.81 eq) was 
dissolved in dry DMSO (400 µL) and DIPEA (2.18 µL, 1.65 mg, 12.8 µmol, 4.00 eq) was 
added. The mixture was added to the resin and treated with microwave irradiation (10 W) 
for 2 h at 37 °C, followed by shaking overnight at 37 °C. The resin was washed with DMF 
(15 × 5 mL), MeOH (15 × 5 mL) and cleaved according to SOP10. The crude peptide was 
purified via semi-preparative HPLC to obtain compound 27 as a blue solid. 
HPLC (semi-preparative, 80-100 % B in 30 min, λ/nm: 215, 280, 643): tR = 33.00 min.  





















Figure 46: DPX addition for P/L ratios of 1:1000 to 1:100 with an outer pH of 8.4 for CA∙M modified peptides 
1 and 2 (a) and the transmembrane domain 21 (b). 
 
 
Figure 47: Time-resolved currents after applying a constant voltage of 150 mV to both sides of the membrane 
with the incorporated transmembrane domain 21 (100 nM) at pH 1.3. 
a)                                                                                      b) 


















Ac2O  acetic anhydride 
ACHC  trans-2-aminocyclohexanecarboxylic acid 
AcOH  acetic acid 
ACPC  trans-2-aminocyclopentanecarboxylic acid 
ATP  adenosine triphosphate 
ATR  attenuated total reflectance 
BFP  blue fluorescent protein 
Boc  tert-butoxycarbonyl 
CA  cyanuric acid 
Calmodulin calcium-modulated protein 
Cbz  benzyloxycarbonyl 
CD  circular dichroismn 
CFP  cyan fluorescent protein 
CLSM  confocal laser scanning microscopy 
DBU  1,8-diazabicyclo[5.4.0]undec-7-en 
DCM  dichloromethane 
DIC  N,N’-diisopropylcarbodiimide 
DIPEA N,N-diisopropylethylamine 
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DLPC  1,2-dilauroyl-sn-glycero-3-phosphocholine 
DLS  dynamic light scattering 
DMF  N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DOPC  1,2-dioleoyl-sn-glycero-3-phosphocholine 
DPX  p-xylene-bis(N-pyridinium bromide) 
EPR  electron paramagnetic resonance 
eq  equivalents 
ESI  electrospray ionization 
Fmoc  fluorenylmethoxycarbonyl 
FRET  FÖRSTER resonance energy transfer 
GFP  green fluorescent protein 
GUV  giant unilamellar vesicle 
HATU  O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophos-
phate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOAt  1-hydroxy-7-azabenzotriazole 
HPLC  high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
IR  infrared 
KALP  peptide model system with a sequence of GKK(LA)nLKKA 
LUV  large unilamellar vesicle 
Lys  lysine 
MES  2-(N-morpholino)ethanesulfonic acid 
MIET  metal-induced energy transfer 
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MLCK myosin light-chain kinase 
Mtt  4-methyltrityl 
NBD  7-nitrobenzofurazan 
NHS  N-hydroxysuccinimide 
NMP  N-methyl-2-pyrrolidone 
NMR  nuclear magnetic resonance 
NSET  nanoparticle-based surface energy transfer 
o.n.  overnight 
OSu  succinimide 
P/L  peptide-to-lipid 
PALM  photoactivated localization microscopy 
PG  protecting group 
pH  pondus hydrogenii 
Ph  phenyl 
pNZ  p-nitrobenzyloxycarbonyl 
POPC  1-palmitoyl-2-oleoyl-glycero-3-phosphocholine 
ppm  parts per million 
PyAOP 7-azabenzotriazole-1-yl-oxy-tris-pyrrolodino-phosphonium hexafluorophos-
phate 
PyBOP benzotriazole-1-yl-oxy-tris-pyrrolodino-phosphonium hexafluorophosphate 
rt  room temperature 
SLB  supported lipid bilayer 
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SPPS  solid-phase peptide synthesis 
STORM stochastic optical reconstruction microscopy 
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TAMRA 5(6)-carboxytetramethylrhodamine 
TCSPC time-correlated single photon counting 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TIS  triisopropylsilan 
TLC  thin layer chromatography 
TMD  transmembrane domain 
TMS  trimethylsilan 
Trp  tryptophan 
UV  ultraviolet 
Val  valine 
Vis  visual 
v/v  volume-to-volume 
WALP  peptide model system with a sequence of GWW(LA)nLWWA 
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